



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/03/31
(87) Date publication PCT/PCT Publication Date: 2017/10/05
(85) Entrée phase nationale/National Entry: 2018/08/01
(86) N° demande PCT/PCT Application No.: EP 2017/057663
(87) N° publication PCT/PCT Publication No.: 2017/167953
(30) Priorité/Priority: 2016/03/31 (EP16163281.5)

(51) Cl.Int./Int.Cl. *C07D 209/26* (2006.01),
A61K 31/404 (2006.01), *A61P 31/12* (2006.01)

(71) Demandeurs/Applicants:
JANSSEN PHARMACEUTICALS, INC., US;
KATHOLIEKE UNIVERSITEIT LEUVEN, BE

(72) Inventeurs/Inventors:
BARDIOT, DOROTHEE ALICE MARIE-EVE, BE;
BONFANTI, JEAN-FRANCOIS, FR;
KESTELEYN, BART RUDOLF ROMANIE, BE;
MARCHAND, ARNAUD DIDIER M, BE;
RABOISSON, PIERRE JEAN-MARIE BERNARD, BE

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : DERIVES D'INDOLINE SUBSTITUEE UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU
VIRUS DE LA DENGUE

(54) Title: SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

(57) **Abrégé/Abstract:**

The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
5 October 2017 (05.10.2017)(10) International Publication Number
WO 2017/167953 A1

- (51) **International Patent Classification:**
C07D 209/26 (2006.01) A61P 31/12 (2006.01)
A61K 31/404 (2006.01)
- (21) **International Application Number:**
PCT/EP2017/057663
- (22) **International Filing Date:**
31 March 2017 (31.03.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
16163281.5 31 March 2016 (31.03.2016) EP
- (71) **Applicants:** JANSSEN PHARMACEUTICALS, INC. [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ New Jersey 08560 (US). KATHOLIEKE UNIVERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, 3000 Leuven (BE).
- (72) **Inventors:** BARDIOT, Dorothee Alice Marie-Eve; c/o Cistim Leuven vzw, Gaston Geenslaan 2, 3001 Leuven (Heverlee) (BE). BONFANTI, Jean-François; c/o Janssen-Cilag, 1 rue Camille Desmoulins, TSA 91003, 92787 Issy-les-Moulineaux Cedex 9 (FR). KESTELEYN, Bart Rudolf Romanie; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). MARCHAND, Arnaud Didier M; c/o Cistim Leuven vzw, Gaston Geenslaan 2, 3001 Leuven (Heverlee) (BE). RABOISSON, Pierre Jean-Marie Bernard; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).
- (74) **Agent:** VERBERCKMOES, Filip; J&J Patent Law Department, Turnhoutseweg 30, 2340 Beerse (BE).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- Published:**
- *with international search report (Art. 21(3))*
 - *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS(57) **Abstract:** The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

WO 2017/167953 A1

SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

The present invention relates to substituted indoline derivatives, methods to
5 prevent or treat dengue viral infections by using said compounds and also relates
to said compounds for use as a medicine, more preferably for use as a medicine
to treat or prevent dengue viral infections. The present invention furthermore
relates to pharmaceutical compositions or combination preparations of the
compounds, to the compositions or preparations for use as a medicine, more
10 preferably for the prevention or treatment of dengue viral infections. The invention
also relates to processes for preparation of the compounds.

BACKGROUND OF THE INVENTION

Flaviviruses, which are transmitted by mosquitoes or ticks, cause life-threatening
15 infections in man, such as encephalitis and hemorrhagic fever. Four distinct, but
closely related serotypes of the flavivirus dengue are known, so-called DENV-1, -2,
-3, and -4. Dengue is endemic in most tropical and sub-tropical regions around the
world, predominantly in urban and semi-urban areas. According to the World
Health Organization (WHO), 2.5 billion people of which 1 billion children are at risk
20 of DENV infection (WHO, 2002). An estimated 50 to 100 million cases of dengue
fever [DF], half a million cases of severe dengue disease (i.e. dengue hemorrhagic
fever [DHF] and dengue shock syndrome [DSS]), and more than 20,000 deaths
occur worldwide each year. DHF has become a leading cause of hospitalization
and death amongst children in endemic regions. Altogether, dengue represents
25 the most common cause of arboviral disease. Because of recent large outbreaks
in countries situated in Latin America, South-East Asia and the Western Pacific
(including Brazil, Puerto Rico, Venezuela, Cambodia, Indonesia, Vietnam,
Thailand), numbers of dengue cases have risen dramatically over the past years.
Not only is the number of dengue cases increasing as the disease is spreading to
30 new areas, but the outbreaks tend to be more severe.

Although progress is being made in the development of vaccines against dengue
with the availability of the Dengvaxia[®] vaccine, many difficulties are encountered.
These include the existence of a phenomenon referred to as antibody-dependent
35 enhancement (ADE). Recovery from an infection by one serotype provides
lifelong immunity against that serotype but confers only partial and transient
protection against a subsequent infection by one of the other three serotypes.

Following infection with another serotype, pre-existing heterologous antibodies form complexes with the newly infecting dengue virus serotype but do not neutralize the pathogen. Instead, virus entry into cells is believed to be facilitated, resulting in uncontrolled virus replication and higher peak viral titers. In both
5 primary and secondary infections, higher viral titers are associated with more severe dengue disease. Since maternal antibodies can easily pass on to infants by breast feeding, this might be one of the reasons that children are more affected by severe dengue disease than adults.

10 In locations with two or more serotypes circulating simultaneously, also referred to as hyper endemic regions, the risk of serious dengue disease is significantly higher due to an increased risk of experiencing a secondary, more severe infection. Moreover, in a situation of hyper-endemicity, the probability of the emergence of more virulent strains is increased, which in turn augments the
15 probability of dengue hemorrhagic fever (DHF) or dengue shock syndrome.

The mosquitoes that carry dengue, including *Aedes aegypti* and *Aedes albopictus* (tiger mosquito), are moving north on the globe. According to the United States (US) Centers for Disease Control and Prevention (CDC), both mosquitoes are
20 currently omnipresent in southern Texas. The spread north of dengue-carrying mosquitoes is not confined to the US, but has also been observed in Europe.

Dengvaxia[®], the dengue vaccine produced by Sanofi Pasteur was first approved in Mexico and has received in the meantime approval in more countries.

25 Nevertheless, the vaccine leaves considerable room for improvement due to limited efficacy, especially against DENV-1 and -2, low efficacy in flavivirus-naïve subjects and the lengthy dosing schedule.

Despite these shortcomings, the vaccine is a game changer in endemic settings
30 as it will offer protection to a large part of the population, but likely not to very young infants, who bear the largest burden of dengue. In addition, the dosing schedule and very limited efficacy in flavivirus-naïve subjects make it unsuitable and likely not worthwhile/cost-effective for travelers from non-endemic areas to dengue-endemic areas. The above mentioned shortcomings of the dengue
35 vaccines are the reason why there is a need for a pre-exposure prophylactic dengue antiviral.

Furthermore, today, specific antiviral drugs for the treatment or prevention of dengue fever virus infection are not available. Clearly, there is still a great unmet medical need for therapeutics for the prevention or treatment of viral infections in animals, more in particular in humans and especially for viral infections caused by
5 Flaviviruses, more in particular Dengue virus. Compounds with good anti-viral potency, no or low levels of side-effects, a broad spectrum activity against multiple Dengue virus serotypes, a low toxicity and/or good pharmacokinetic or -dynamic properties are highly needed.

10 WO-2010/021878 discloses 2-phenylpyrrolidine and indoline derivatives as cold menthol receptor antagonists for treatment of inflammatory and central diseases. WO-2013/045516 discloses indole or indoline derivatives for use in the treatment of dengue viral infections.

15 The present invention now provides compounds, substituted indoline derivatives, which show high potent activity against all four (4) serotypes of the Dengue virus.

SUMMARY OF THE INVENTION

The present invention is based on the unexpected finding that at least one of the
20 above-mentioned problems can be solved by the current compounds of the invention.


The present invention provides compounds which have been shown to possess potent antiviral activity against all four (4) serotypes currently known. The present
25 invention furthermore demonstrates that these compounds efficiently inhibit proliferation of Dengue virus (DENV). Therefore, these compounds constitute a useful class of potent compounds that can be used in the treatment and/or prevention of viral infections in animals, mammals and humans, more specifically for the treatment and/or prevention of infections with Dengue viruses.

30 The present invention furthermore relates to the use of such compounds as medicines and to their use for the manufacture of medicaments for treating and/or preventing viral infections, in particular with viruses belonging to the family of the Dengue viruses in animals or mammals, more in particular in humans. The
35 invention also relates to methods for the preparation of all such compounds and to pharmaceutical compositions comprising them in an effective amount.

The present invention also relates to a method of treatment or prevention of dengue viral infections in humans by the administration an effective amount of one or more







such compounds, or a pharmaceutically acceptable salt thereof optionally in combination with one or more other medicines, like another antiviral agent, to a patient in need thereof.








- 5 One aspect of the invention is the provision of compounds having formula (I), a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof :



wherein the compounds are selected from the group comprising:


10





5

In an alternative embodiment, the present invention relates to a compound having formula (I)



a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein

R₁ is trifluoromethyl, R₂ is hydrogen, R₃ is hydrogen, and R is methoxy; or

R₁ is trifluoromethyl, R₂ is hydrogen, R₃ is hydrogen, and R is fluoro; or

5 R₁ is trifluoromethoxy, R₂ is hydrogen, R₃ is hydrogen, and R is hydrogen; or

R₁ is trifluoromethyl, R₂ is hydrogen, R₃ is hydrogen, and R is hydrogen; or

R₁ is trifluoromethoxy, R₂ is hydrogen, R₃ is hydrogen, and R is methoxy; or

R₁ is trifluoromethoxy, R₂ is hydrogen, R₃ is hydrogen, and R is fluoro; or

R₁ is trifluoromethyl, R₂ is methoxy, R₃ is hydrogen, and R is hydrogen; or

10 R₁ is trifluoromethyl, R₂ is methoxy, R₃ is hydrogen, and R is fluoro; or

R₁ is trifluoromethoxy, R₂ is hydrogen, R₃ is methyl, and R is hydrogen; or

R₁ is trifluoromethyl, R₂ is hydrogen, R₃ is methyl, and R is hydrogen; or

R₁ is trifluoromethyl, R₂ is methoxy, R₃ is hydrogen, and R is methoxy; or

R₁ is trifluoromethyl, R₂ is fluoro, R₃ is hydrogen, and R is hydrogen; or

15 R₁ is trifluoromethoxy, R₂ is methoxy, R₃ is hydrogen, and R is hydrogen.

Part of the current invention is also a pharmaceutical composition comprising a compound mentioned above or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof together with one or more

20 pharmaceutically acceptable excipients, diluents or carriers.

Pharmaceutically acceptable salts of said compounds include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-

25 toxic salts.

The compounds of the invention may also exist in un-solvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.

30

The term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure.

The compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray

35 drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or

more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term “excipient” is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral or rectal administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

10 The exact dosage and frequency of administration depends on the particular compound of the invention used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

20 The present disclosure is also intended to include any isotopes of atoms present in the compounds of the invention. For example, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include C-13 and C-14.

25 The present compounds used in the current invention may also exist in their stereochemically isomeric form, defining all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures, which are not interchangeable. Unless otherwise mentioned or indicated, the chemical designation of compounds encompasses the mixture of all possible stereochemically isomeric forms, which said compounds might possess.


30 Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds used in the present invention either in pure form or in admixture with each other are intended to be embraced within the scope of the present invention including any racemic mixtures or racemates.

Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomerically pure' concerns
 5 compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric
 10 excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar way, but then having regard to the enantiomeric excess, respectively the diastereomeric excess of the mixture in question.

15

Pure stereoisomeric forms of compounds and intermediates used in this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof
 20 are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs
 25 stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (I) of the present invention all have at least one chiral
 30 carbon atom as indicated in the figure below by the carbon atom labelled with * :



Due to the presence of said chiral carbon atom, a "compound of formula (I)" can be the (R)-enantiomer, the (S)-enantiomer, the racemic form, or any possible combination of the two individual enantiomers in any ratio. When the absolute (R)- or (S)-configuration of an enantiomer is not known, this enantiomer can also be identified by indicating whether the enantiomer is dextrorotatory (+)- or levorotatory (-)- after measuring the specific optical rotation of said particular enantiomer.

10 In an aspect the present invention relates to a first group of compound of formula (I) wherein the compounds of formula (I) have the (+) specific rotation.

In a further aspect the present invention relates to a second group of compounds of formula (I) wherein the compounds of formula (I) have the (-) specific rotation.

15

Examples

LC/MS methods

High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).

Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

Compounds are described by their experimental retention times (R_t) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the $[M+H]^+$ (protonated molecule) and/or $[M-H]^-$ (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. $[M+NH_4]^+$, $[M+HCOO]^-$, etc...). For molecules with multiple isotopic patterns (Br, Cl), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.

Hereinafter, "SQD" means Single Quadrupole Detector, "MSD" Mass Selective Detector, "RT" room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD" Diode Array Detector, "HSS" High Strength silica.

LC/MS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes)

Method code	Instrument	Column	Mobile phase	Gradient	Flow ----- Col T	Run time (min)
LC-A	Waters: Acquity® UPLC® - DAD-Quattro Micro™	Waters BEH C18 (1.7µm, 2.1x100mm)	A: 95% CH ₃ COONH ₄ 7mM / 5% CH ₃ CN, B: CH ₃ CN	84.2% A for 0.49 min, to 10.5% A in 2.18 min, held for 1.94 min, back to 84.2% A in 0.73 min, held for 0.73 min.	0.343 mL/min ----- 40°C	6.2
LC-B	Waters: Acquity® H- Class - DAD and SQD2™	Waters BEH C18 (1.7µm, 2.1x100mm)	A: 95% CH ₃ COONH ₄ 7mM / 5% CH ₃ CN, B: CH ₃ CN	84.2% A/15.8% B to 10.5% A in 2.18 min, held for 1.96 min, back to 84.2% A/15.8% B in 0.73 min, held for 0.49 min.	0.343 mL/min ----- 40°C	6.1

SFC/MS methods

- 5 The SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon dioxide (CO₂) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is
- 10 within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

- 15 Analytical SFC/MS Methods (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes, Backpressure (BPR) in bars.

Method code	column	mobile phase	gradient	Flow ----- Col T	Run time ----- BPR
SFC-A	Daicel Chiralcel® OD column (5 µm, 150 x 4.6 mm)	A: CO ₂ B: MeOH	40% B hold 7 min	3 ----- 35	7 ----- 100

Method code	column	mobile phase	gradient	Flow ----- Col T	Run time ----- BPR
SFC-B	Daicel Chiralcel® OD-3 column (3 µm, 100 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	40% B hold 3 min	3.5 ----- 35	3 ----- 103
SFC-C	Daicel Chiralpak® IA column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	40% B hold 7 min	3.5 ----- 35	7 ----- 103
SFC-D	Daicel Chiralcel® OJ-H column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	40% B hold 7 min	3 ----- 35	7 ----- 100
SFC-E	Daicel Chiralpak® IC-3 column (3 µm, 100 x 4.6 mm)	A:CO ₂ B: iPrOH (+0.3% iPrNH ₂)	30% B hold 5min	3.5 ----- 35	5 ----- 103
SFC-F	Daicel Chiralcel® OD column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	30% B hold 7 min	3 ----- 35	7 ----- 100
SFC-G	Daicel Chiralpak® IA column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: iPrOH (+0.3% iPrNH ₂)	50% B hold 7 min	3 ----- 35	7 ----- 100
SFC-H	Daicel Chiralpak® IA column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	30% B hold 7 min	3 ----- 35	7 ----- 100
SFC-I	Daicel Chiralpak® IA column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	50% B hold 7 min	3.5 ----- 35	7 ----- 103
SFC-J	Daicel Chiralpak® IC column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	40% B hold 7 min	3 ----- 35	7 ----- 100

Melting Points

Values are either peak values or melt ranges, and are obtained with experimental uncertainties that are commonly associated with this analytical method.

5 **DSC823e (indicated as DSC)**

For a number of compounds, melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 10°C/minute. Maximum temperature was 300°C.

10 **Optical Rotations:**


Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp and reported as follows: $[\alpha]^T (\lambda, c \text{ g/100ml, solvent, } T^\circ\text{C})$.

$[\alpha]_{\lambda}^T = (100\alpha) / (l \times c)$: where l is the path length in dm and c is the concentration in g/100 ml for a sample at a temperature T ($^\circ\text{C}$) and a wavelength λ (in nm). If the

15 wavelength of light used is 589 nm (the sodium D line), then the symbol D might be used instead. The sign of the rotation (+ or -) should always be given. When using this equation the concentration and solvent are always provided in parentheses after the rotation. The rotation is reported using degrees and no units of concentration are given (it is assumed to be g/100 ml).

20

Example 1 : synthesis of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **1**) and chiral separation into Enantiomers **1A** and **1B**.



Synthesis of intermediate 1a:

A mixture of 2-(4-chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (1.55 g, 7.75 mmol) and 6-(trifluoromethyl)indoline [CAS 181513-29-1] (1.45 g, 7.75 mmol), HOBt (2.78 g, 11.6 mmol), EDCI (2.23 g, 11.6 mmol) and triethylamine (2.15 mL, 15.5 mmol) in CH₂Cl₂ (40 mL) was stirred at room temperature for 12 h. Water was added and the layers were separated. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm, 120 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **1a** (1.66 g).

Synthesis of intermediate 1b:

At -78°C, under a N₂ flow, LiHMDS 1M in THF (8.98 mL, 8.98 mmol) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **1a** (1.66 g, 4.49 mmol) in THF (18 mL). The mixture was stirred for 15 min at -78°C and a solution of NBS (879 mg, 4.94 mmol) in THF (7 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched by the addition of a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm, 40 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **1b** (1.23 g).

Synthesis of Compound 1 and chiral separation into Enantiomers 1A and 1B:

A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **1b** (1.2 g, 2.68 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (735 mg, 4.01 mmol) and triethylamine (558 μL, 4.01 mmol) in CH₃CN (50 mL) was stirred at 70°C for 6 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl. The organic phase was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μm, 40 g, CH₂Cl₂/MeOH 97.5/2.5). The pure fractions were combined and evaporated to dryness to give racemic 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **1**, 900 mg) after crystallization from CH₃CN. This batch was combined with 2 other batches (total amount: 1.84 g). The enantiomers were

separated via Preparative Chiral SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 30mm, Mobile phase: 55% CO₂, 45% MeOH). The first eluted enantiomer was further purified by flash chromatography on silica gel (15-40 µm, 40 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were combined and evaporated to dryness to give, after solidification in petroleum ether/CH₃CN/diisopropyl ether, Enantiomer **1A** (540 mg). The second eluted enantiomer was further purified by flash chromatography on silica gel (15-40 µm, 40 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were combined and evaporated to dryness to give, after solidification in petroleum ether/CH₃CN/diisopropyl ether, Enantiomer **1B** (560 mg).

Compound 1:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.24 (m, 2 H) 3.59 - 3.67 (m, 5 H) 3.78 - 3.87 (m, 2 H) 3.90 (s, 3 H) 3.98 - 4.07 (m, 1 H) 4.33 - 4.42 (m, 1 H) 4.79 (br t, *J*=4.7 Hz, 1 H) 5.60 (d, *J*=8.5 Hz, 1 H) 5.76 (s, 1 H) 5.87 (br s, 2 H) 6.44 (br d, *J*=8.5 Hz, 1 H) 7.03 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.15 (d, *J*=1.6 Hz, 1 H) 7.32 (d, *J*=8.5 Hz, 1 H) 7.39 (d, *J*=7.9 Hz, 1 H) 7.46 (d, *J*=7.9 Hz, 1 H) 8.36 (s, 1 H)

LC/MS (method LC-A): R_t 3.35 min, MH⁺ 551

Melting point: 194°C

Enantiomer 1A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.16 - 3.30 (m, 2 H) 3.57 - 3.67 (m, 5 H) 3.79 - 3.88 (m, 2 H) 3.90 (s, 3 H) 4.03 (td, *J*=10.3, 7.1 Hz, 1 H) 4.37 (td, *J*=10.1, 6.6 Hz, 1 H) 4.79 (t, *J*=5.4 Hz, 1 H) 5.61 (d, *J*=8.5 Hz, 1 H) 5.77 (t, *J*=1.9 Hz, 1 H) 5.87 (br s, 2 H) 6.44 (d, *J*=8.8 Hz, 1 H) 7.03 (dd, *J*=8.2, 2.2 Hz, 1 H) 7.15 (d, *J*=1.9 Hz, 1 H) 7.32 (d, *J*=8.2 Hz, 1 H) 7.39 (d, *J*=7.9 Hz, 1 H) 7.46 (d, *J*=7.6 Hz, 1 H) 8.37 (s, 1 H)

LC/MS (method LC-A): R_t 3.34 min, MH⁺ 551

[α]_D²⁰: -26.5° (c 0.3091, DMF)

Chiral SFC (method SFC-A): R_t 1.45 min, MH⁺ 551, chiral purity 100%.

Enantiomer 1B:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.20 - 3.30 (m, 2 H) 3.58 - 3.68 (m, 5 H) 3.80 - 3.88 (m, 2 H) 3.91 (s, 3 H) 4.03 (td, *J*=10.2, 7.1 Hz, 1 H) 4.38 (td, *J*=10.2, 6.6 Hz, 1 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.61 (d, *J*=8.8 Hz, 1 H) 5.77 (t, *J*=2.0 Hz, 1 H) 5.88 (br s, 2 H) 6.45 (d, *J*=8.5 Hz, 1 H) 7.04 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.15 (d, *J*=1.9 Hz, 1 H) 7.32 (d, *J*=8.2 Hz, 1 H) 7.39 (d, *J*=7.6 Hz, 1 H) 7.47 (d, *J*=7.9 Hz, 1 H) 8.37 (s, 1 H)


LC/MS (method LC-A): R_t 3.34 min, MH⁺ 551

[α]_D²⁰: +28.8° (c 0.2845, DMF)

Chiral SFC (method SFC-A): R_t 3.64 min, MH^+ 551, chiral purity 100%.

Example 2.1 : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **2**).

5



Synthesis of intermediate **2a**:

A mixture of 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (504 mg, 2.67 mmol) and 6-(trifluoromethyl)indoline [CAS 181513-29-1] (500 mg, 2.67 mmol), HOBt (541 mg, 4 mmol), EDCl (768 mg, 4 mmol) and triethylamine (743 μL , 5.34 mmol) in CH_2Cl_2 (6 mL) was stirred at room temperature for 12 h. Water was added and the layers were separated. The organic layer was washed with water, dried over $MgSO_4$, filtered, and the solvent was evaporated under reduced pressure to give 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **2a** (1.04 g). The compound was used as such in the next step.

Synthesis of intermediate **2b**:

At $-78^\circ C$, under a N_2 flow, LiHMDS 1M in THF (5.5 mL, 5.5 mmol) was added dropwise to a solution of 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **2a** (980 mg, 2.74 mmol) in THF (8 mL). The reaction mixture was stirred for 15 min at $-78^\circ C$ and a solution of NBS (536 mg, 3.01 mmol) in THF (5 mL) was added dropwise. After stirring for 2 h at $-78^\circ C$, the reaction was quenched by the addition of a saturated aqueous solution of NH_4Cl . The mixture was extracted with EtOAc, dried over $MgSO_4$, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-fluorophenyl)-

1-(6-(trifluoromethyl)indolin-1-yl)ethanone **2b** (1.3 g). The compound was used as such in the next step.

Synthesis of Compound 2:

5 A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)-ethanone **2b** (500 mg, 1.15 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (315 mg, 1.72 mmol) and triethylamine (296 μ L, 1.72 mmol) in CH₃CN (5 mL) was stirred at 50°C for 24 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl. The organic
10 phase was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μ m, 24 g, heptane/EtOAc gradient 70/30 to 50/50). The pure fractions were combined and evaporated to dryness to give 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)-
15 indolin-1-yl)ethanone (Compound **2**, 136 mg) after crystallization from Et₂O.


Compound 2:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.20 - 3.28 (m, 2 H) 3.57 - 3.69 (m, 5 H) 3.79 - 3.91 (m, 2 H) 4.03 - 4.13 (m, 1 H) 4.39 - 4.49 (m, 1 H) 4.78 (br s, 1 H) 5.71 (d, *J*=9.1 Hz, 1 H) 5.77 - 5.82 (m, 1 H) 5.93 (d, *J*=2.0 Hz, 2 H) 6.59 (d, *J*=9.1 Hz, 1 H) 7.32 (dd, *J*=8.3, 1.8 Hz, 1 H) 7.38 - 7.51 (m, 4 H) 8.36 (s, 1 H)

LC/MS (method LC-A): R_t 3.36 min, MH⁺ 539

Melting point: 168°C

25 **Example 2.2** : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **2**) and chiral separation into Enantiomers **2A** and **2B**.



Synthesis of intermediate 2c:

At -78°C, under a N₂ flow, LiHMDS 1M in THF (38.5 mL, 38.5 mmol) was added dropwise to a mixture of methyl 2-(4-chloro-2-fluorophenyl)acetate [CAS 917023-04-2] (3.9 g, 19.3 mmol) in THF (120 mL). A solution of TMSCl (3.9 mL, 30.8 mmol) in THF (30 mL) was added dropwise. The mixture was stirred for 15 min at -78°C and a solution of NBS (3.77 g, 21.2 mmol) in THF (50 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched by the addition of a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure to give methyl 2-bromo-2-(4-chloro-2-fluorophenyl)acetate **2c** (5.4 g). The compound was used as such in the next step.

Synthesis of intermediate 2d:

A mixture of methyl 2-bromo-2-(4-chloro-2-fluorophenyl)acetate **2c** (4 g, 12.8 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (2.1 g, 11.6 mmol), triethylamine (2.4 mL, 17.4 mmol) in CH₃CN (80 mL) was stirred at 50°C for 12 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with water. The organic phase was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were combined and evaporated to dryness to give methyl 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **2d** (2.1 g).

Synthesis of intermediate 2e:

A mixture of methyl 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **2d** (1 g, 2.6 mmol) and LiOH (330 mg, 7.8 mmol) in THF/water (1/1) (40 mL) was stirred at room temperature for 1 h. The mixture was diluted with water. The aqueous layer was slowly acidified with 3N HCl and extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure to give 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **2e** (2.7 g). The compound was used as such in the next step.

Synthesis of Compound 2 and chiral separation into Enantiomers 2A and 2B:

HATU (1.85 g, 4.87 mmol) was added to a mixture of 6-(trifluoromethyl)indoline [CAS 181513-29-1] (607 mg, 3.24 mmol), 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **2e** (1.2 g, 3.24 mmol) and

diisopropylethylamine (1.6 mL, 9.74 mmol) in DMF (35 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with water and the precipitate was filtered off. The solids were washed with water and taken up in EtOAc. The organic solution was washed with a 10% solution of K₂CO₃ in water and brine, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). A second purification was performed via achiral SFC (Stationary phase: 2-Ethylpyridine 5 μm 150 x 30mm, Mobile phase: 70% CO₂, 30% MeOH) to afford 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **2**, 550 mg) as a racemic mixture. This batch was combined with another batch (total amount: 950 mg). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IA 5 μm 250 x 20 mm, Mobile phase: 70% CO₂, 30% iPrOH (+ 0.3% iPrNH₂)) to give, after solidification in petroleum ether/diisopropyl ether, the first eluted Enantiomer **2A** (384 mg) and the second eluted Enantiomer **2B** (375 mg).

Enantiomer 2A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.20 - 3.29 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.85 (dq, *J*=10.6, 5.2 Hz, 2 H) 4.08 (td, *J*=10.1, 7.3 Hz, 1 H) 4.40 - 4.48 (m, 1 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.71 (d, *J*=8.8 Hz, 1 H) 5.80 (t, *J*=2.0 Hz, 1 H) 5.93 (d, *J*=1.9 Hz, 2 H) 6.61 (d, *J*=8.8 Hz, 1 H) 7.33 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.38 - 7.51 (m, 4 H) 8.36 (s, 1 H)

LC/MS (method LC-A): R_t 3.34 min, MH⁺ 539

[α]_D²⁰: -26.4° (c 0.2691, DMF)

Chiral SFC (method SFC-B): R_t 0.83 min, MH⁺ 539, chiral purity 100%.

Enantiomer 2B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.21 - 3.29 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.85 (tq, *J*=10.4, 5.0 Hz, 2 H) 4.04 - 4.12 (m, 1 H) 4.40 - 4.48 (m, 1 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.71 (d, *J*=8.8 Hz, 1 H) 5.78 - 5.81 (m, 1 H) 5.93 (d, *J*=1.6 Hz, 2 H) 6.61 (d, *J*=8.8 Hz, 1 H) 7.33 (dd, *J*=8.5, 1.9 Hz, 1 H) 7.39 - 7.52 (m, 4 H) 8.36 (s, 1 H)

LC/MS (method LC-A): R_t 3.34 min, MH⁺ 539

[α]_D²⁰: +27.3° (c 0.2564, DMF)

Chiral SFC (method SFC-B): R_t 1.69 min, MH⁺ 539, chiral purity 99.07%.

Example 3.1 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **3**) and chiral separation into Enantiomers **3A** and **3B**.



5 Synthesis of intermediate **3a**:

Benzoyl peroxide (5 mg) was added to a mixture of methyl 2-(4-chlorophenyl)-acetate [CAS 52449-43-1] (5.0 g, 29.7 mmol) and NBS (4.82 g, 27.1 mmol) in CH_3CN (80 mL). The mixture was heated under reflux for 48 h and the solvent was evaporated under reduced pressure. The mixture was taken up in cyclohexane/EtOAc 80/20 and the precipitate was filtered off and discarded (succinimide). The filtrate was concentrated under reduced pressure to give methyl 2-bromo-2-(4-chlorophenyl)acetate **3a** (7.2 g). The compound was used as such in the next step.

15 Synthesis of intermediate **3b**:

A mixture of methyl 2-bromo-2-(4-chlorophenyl)acetate **3a** (6 g, 3.80 mmol), 3-(2-(*tert*-butoxy)ethoxy)-5-methoxyaniline [CAS 1428973-39-0] (4.63, 4.05 mmol), triethylamine (4.04 mL, 29.0 mmol) in CH_3CN (30 mL) was stirred at 50°C for 12h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with water. The organic phase was separated, dried over MgSO_4 , filtered, and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 μm , 40 g, heptane/EtOAc 90/10). The pure fractions were combined and evaporated to dryness to give

methyl 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-acetate **3b** (4.8 g).

Synthesis of intermediate **3c**:

5 A mixture of methyl 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)acetate **3b** (4.8 g, 11.4 mmol) and LiOH (1.43 mg, 34.1 mmol) in THF/water (1/1) (50 mL) was stirred at room temperature for 1 h. The mixture was diluted with water. The aqueous layer was slowly acidified with 3N HCl and extracted with EtOAc. The combined organic layers were dried over MgSO₄,
10 filtered, and the solvent was evaporated under reduced pressure to give 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)acetic acid **3c** (4.6 g). The compound was used as such in the next step.

Synthesis of intermediate **3d**:

15 HATU (2.10 g, 5.52 mmol) was added to a mixture of 6-(trifluoromethoxy)indoline [CAS 953906-76-8] (747 mg, 3.68 mmol), 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)acetic acid **3c** (1.5 g, 3.68 mmol) and diisopropylethylamine (1.82 mL, 11.03 mmol) in DMF (30 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with
20 water and extracted with EtOAc. The organic layer was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm, 40 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chloro-
25 phenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **3d** (1.33 g).

Synthesis of Compound **3** chiral separation into Enantiomers **3A** and **3B**:

A mixture of 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **3d** (1.33 g, 2.24 mmol) in 4M
30 HCl in dioxane (25 mL) was stirred at room temperature for 18 h. The mixture was diluted with water and was basified with K₂CO₃. The aqueous layer was extracted with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm, 40 g, CH₂Cl₂/MeOH/NH₄OH
35 99/1/0.1). The pure fractions were combined and evaporated to dryness to afford 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **3** (1 g) as a racemic mixture. The enantiomers were separated via Preparative Chiral SFC (Stationary phase:

Chiralpak® IA 5 µm 250 x 20 mm, Mobile phase: 55% CO₂, 40% EtOH (+ 0.3% iPrNH₂), 5% CH₂Cl₂). The enantiomers were further separated via preparative chiral SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 30 mm, Mobile phase: 50% CO₂, 50% EtOH (+ 0.3% iPrNH₂)) to give, after solidification in petroleum ether/diisopropyl ether, the first eluted Enantiomer **3A** (294 mg) and the second eluted Enantiomer **3B** (244 mg).

Compound 3:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.08 - 3.25 (m, 2 H) 3.58 - 3.68 (m, 5 H) 3.79 - 3.89 (m, 2 H) 4.00 - 4.11 (m, 1 H) 4.47 - 4.57 (m, 1 H) 4.79 (t, *J*=5.4 Hz, 1 H) 5.56 (br d, *J*=8.8 Hz, 1 H) 5.76 (s, 1 H) 5.94 (s, 2 H) 6.47 (br d, *J*=8.5 Hz, 1 H) 7.01 (br d, *J*=7.9 Hz, 1 H) 7.34 (d, *J*=8.2 Hz, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.55 (br d, *J*=8.2 Hz, 2 H) 8.03 (br s, 1 H)

LC/MS (method LC-A): R_t 3.36 min, MH⁺ 537

Melting point: 162°C

Enantiomer 3A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.08 - 3.25 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.79 - 3.89 (m, 2 H) 4.05 (td, *J*=10.4, 7.3 Hz, 1 H) 4.52 (td, *J*=10.4, 6.3 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.56 (d, *J*=8.8 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=1.9 Hz, 2 H) 6.47 (d, *J*=8.5 Hz, 1 H) 7.01 (dd, *J*=8.0, 1.7 Hz, 1 H) 7.33 (d, *J*=8.2 Hz, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.55 (d, *J*=8.5 Hz, 2 H) 8.03 (s, 1 H)

LC/MS (method LC-A): R_t 3.36 min, MH⁺ 537

[α]_D²⁰: +51.9° (c 0.2736, DMF)

Chiral SFC (method SFC-C): R_t 2.55 min, MH⁺ 537, chiral purity 100%.

Enantiomer 3B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.08 - 3.26 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.80 - 3.90 (m, 2 H) 4.05 (td, *J*=10.4, 7.3 Hz, 1 H) 4.52 (td, *J*=10.4, 6.3 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.56 (d, *J*=8.8 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=1.6 Hz, 2 H) 6.47 (d, *J*=8.5 Hz, 1 H) 7.01 (dd, *J*=8.2, 1.6 Hz, 1 H) 7.34 (d, *J*=8.2 Hz, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.55 (d, *J*=8.5 Hz, 2 H) 8.03 (s, 1 H)

LC/MS (method LC-A): R_t 3.36 min, MH⁺ 537

[α]_D²⁰: -51.1° (c 0.2973, DMF)

Chiral SFC (method SFC-C): R_t 3.56 min, MH⁺ 537, chiral purity 99.58%.

Example 3.2 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **3**) and chiral separation into Enantiomers **3A** and **3B**.



Synthesis of intermediate **3e**:

A mixture of methyl 2-bromo-2-(4-chlorophenyl)acetate **3a** (19.2 g, 72.9 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (13.4 g, 72.9 mmol) and triethylamine (15.2 mL, 109.3 mmol) in CH₃CN (115 mL) was heated under reflux for 3h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl. The organic phase was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure to give crude intermediate **3e** (30 g). This fraction was combined with another batch of crude intermediate **3e** (total amount: 37 g) and purified by flash chromatography on silica gel (15-40 μm, 400 g, heptane/EtOAc 60/40). The pure fractions were combined and evaporated to dryness to give methyl 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **3e** (26 g).

10

15

Synthesis of intermediate **3f**:

A mixture of methyl 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **3e** (10 g, 27.3 mmol) and LiOH (3.44 g, 82.0 mmol) in THF/water (1/1) (200 mL) was stirred at room temperature for 2 h. The mixture was diluted with water. The aqueous layer was slowly acidified with 3N HCl and extracted with EtOAc. The organic layers were washed with water, separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure to give 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **3f** (9.5 g). The compound was used as such in the next step.


20

25

Synthesis of Compound 3 and chiral separation into Enantiomers 3A and 3B:

Under N₂ flow at 5°C, propylphosphonic anhydride (2.56 mL, 4.26 mmol) was added dropwise to a mixture of 6-(trifluoromethoxy)indoline [CAS 953906-76-8] (577 mg, 2.84 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **3f** (1.3 g, 3.70 mmol) and diisopropylethylamine (1.03 mL, 6.25 mmol) in 2-Me-THF (30 mL). The mixture was stirred at room temperature for 4 h. Water was added and the mixture was extracted with EtOAc. The organic layer was washed with a 10% solution of K₂CO₃ in water and then with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel, (15-40 μm, 40 g, CH₂Cl₂/MeOH 99/1). The pure fractions were combined and evaporated to dryness, to give 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **3**, 800 mg) as a racemic mixture. This fraction was combined with another batch (total amount: 1.4 g) and crystallized from diisopropyl ether to give 1.03 g of Compound **3**. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IA 5 μm 250 x 20 mm, Mobile phase: 55% CO₂, 45% EtOH (+ 0.3% iPrNH₂)). The first eluted enantiomer was further purified via reverse phase chromatography (stationary phase: X-bridge-C-18 10 μm 30 x 150 mm, mobile phase: 0.2% NH₄HCO₃/CH₃CN gradient 60/40 to 0/100) to give Enantiomer **3A** (312 mg). The second eluted Enantiomer **3B** (436 mg) was not further purified.

Example 4 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **4**) and chiral separation into Enantiomers **4A** and **4B**.



Synthesis of intermediate 4a:

HATU (2.24 g, 5.88 mmol) was added to a mixture of 6-(trifluoromethyl)indoline [CAS 181513-29-1] (734 mg, 3.92 mmol), 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)acetic acid **3c** (1.6 g, 3.92 mmol) and
5 diisopropylethylamine (1.95 mL, 11.8 mmol) in DMF (30 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with water and EtOAc. The organic layer was separated, washed with a 10% solution of K₂CO₃ in water, washed with brine, dried over MgSO₄, filtered, and the solvent was concentrated under reduced pressure. The crude residue was purified by column
10 chromatography on silica gel (15-40 μm, 40 g, heptane/EtOAc 85/15). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **4a** (1.38 g).

15 Synthesis of Compound 4 and chiral separation into Enantiomers 4A and 4B:

2-((3-(2-(*tert*-Butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone **4a** (1.38 g, 2.39 mmol) was mixed with 4M HCl in dioxane (25 mL) stirred at room temperature for 18 h. The mixture was diluted with water and basified with K₂CO₃. The aqueous layer was extracted with
20 EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm, 40 g, CH₂Cl₂/MeOH/NH₄OH 99/1/0.1). The pure fractions were combined and evaporated to dryness to afford 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **4**, 1.08 g) as a racemic
25 mixture. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel® OJ-H 5 μm 250 x 20 mm, Mobile phase: 60% CO₂, 40% EtOH (+ 0.3% *i*PrNH₂)). The first eluted enantiomer (413 mg) was solidified in heptane/ to give Enantiomer **4A** (327 mg). The second eluted enantiomer (410 mg) was
30 solidified in heptane/diisopropyl ether to give Enantiomer **4B** (330 mg).

Compound 4:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.16 - 3.32 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.79 - 3.90 (m, 2 H) 4.03 (td, *J*=10.4, 6.9 Hz, 1 H) 4.53 (td, *J*=10.3, 6.5 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.58 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.95 (s, 2 H) 6.44 (d, *J*=8.5 Hz, 1 H) 7.37 - 7.41 (m, 1 H) 7.43 - 7.49 (m, 3 H) 7.56 (d, *J*=8.5 Hz, 2 H) 8.38 (s, 1 H)

LC/MS (method LC-A): R_t 3.31 min, MH⁺ 521

Melting point: 160°C

Enantiomer 4A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.15 - 3.29 (m, 2 H) 3.58 - 3.70 (m, 5 H) 3.79
5 - 3.89 (m, 2 H) 4.03 (td, *J*=10.4, 7.6 Hz, 1 H) 4.53 (td, *J*=10.2, 6.3 Hz, 1 H) 4.78 (br
s, 1 H) 5.57 (d, *J*=9.1 Hz, 1 H) 5.74 - 5.80 (m, 1 H) 5.95 (d, *J*=1.0 Hz, 2 H) 6.43 (br
d, *J*=8.6 Hz, 1 H) 7.36 - 7.41 (m, 1 H) 7.42 - 7.49 (m, 3 H) 7.56 (d, *J*=8.6 Hz, 2 H)
8.38 (s, 1 H)

LC/MS (method LC-B): *R*_t 3.03 min, *MH*⁺ 521

10 [α]_D²⁰: +52.0° (c 0.3036, DMF)

Chiral SFC (method SFC-D): *R*_t 1.82 min, *MH*⁺ 521, chiral purity 100%.

Enantiomer 4B:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.18 - 3.29 (m, 2 H) 3.59 - 3.70 (m, 5 H) 3.84
15 (m, 2 H) 3.97 - 4.10 (m, 1 H) 4.46 - 4.59 (m, 1 H) 4.78 (br s, 1 H) 5.57 (br d,
J=8.6 Hz, 1 H) 5.76 (s, 1 H) 5.95 (s, 2 H) 6.43 (br d, *J*=8.6 Hz, 1 H) 7.35 - 7.50 (m,
4 H) 7.56 (br d, *J*=8.6 Hz, 2 H) 8.38 (s, 1 H)


LC/MS method LC-B): *R*_t 3.03 min, *MH*⁺ 521

[α]_D²⁰: -51.8° (c 0.3418, DMF)

20 Chiral SFC (method SFC-D): *R*_t 3.17 min, *MH*⁺ 521, chiral purity 99.56%.

Example 5 : synthesis of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-
5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound
5) and chiral separation into Enantiomers **5A** and **5B**.

25



Synthesis of intermediate 5a:

A mixture of 6-(trifluoromethoxy)indoline [CAS 953906-76-8] (1 g, 4.92 mmol), 2-(4-chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (1.09 g, 5.41 mmol), HATU (2.81 g, 7.38 mmol) and diisopropylethylamine (2.44 mL, 14.8 mmol) in DMF (10 mL) was stirred at room temperature for 12 h. Water and EtOAc were added and the layers were separated. The organic layer was washed with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 μm, 80 g, heptane/EtOAc 85/15). The pure fractions were combined and the solvent was concentrated under reduced pressure to give, after crystallization from CH₃CN/heptane, 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **5a** (1.53 g).

Synthesis of intermediate 5b:

At -78°C, under a N₂ flow, LiHMDS 1M in THF (7.93 mL, 7.93 mmol) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **5a** (1.53 g, 3.97 mmol) in THF (12 mL). The mixture was stirred for 15 min at -78°C and a solution of NBS (776 mg, 4.36 mmol) in THF (10 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched by the addition of a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **5b** (1.70 g). The compound was used as such in the next step.

Synthesis of Compound 5 and chiral separation into Enantiomers 5A and 5B:

A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **5b** (1.37 g, 2.95 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (810 mg, 4.42 mmol) and diisopropylethylamine (762 μL, 4.42 mmol) in CH₃CN (20 mL) was stirred at 50°C for 8 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl. The organic phase was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 98.5/1.5). The pure fractions were combined and evaporated to dryness to give, after crystallization from CH₃CN, 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **5**, 500 mg) as a racemic mixture. This batch was combined with another batch

(total amount: 903 mg). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IC 5 μ m 250 x 30 mm, Mobile phase: 65% CO₂, 35% iPrOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (453 mg) was solidified in petroleum ether/diisopropyl ether to give Enantiomer **5A** (355 mg). The
5 second eluted enantiomer (436 mg) was solidified in petroleum ether/diisopropyl ether to give Enantiomer **5B** (342 mg).

Compound 5:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.11 - 3.23 (m, 2 H) 3.59 - 3.67 (m, 5 H) 3.79
10 - 3.87 (m, 2 H) 3.90 (s, 3 H) 4.01 - 4.09 (m, 1 H) 4.32 - 4.41 (m, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.59 (d, *J*=8.5 Hz, 1 H) 5.76 (s, 1 H) 5.87 (br s, 2 H) 6.46 (br d, *J*=8.8 Hz, 1 H) 6.98 - 7.06 (m, 2 H) 7.14 (d, *J*=1.6 Hz, 1 H) 7.30 - 7.35 (m, 2 H) 8.02 (s, 1 H)

LC/MS (method LC-A): R_t 3.38 min, MH⁺ 567

15 Melting point: 162°C

Enantiomer 5A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.10 - 3.25 (m, 2 H) 3.59 - 3.67 (m, 5 H) 3.78
20 - 3.88 (m, 2 H) 3.90 (s, 3 H) 4.04 (td, *J*=10.3, 7.1 Hz, 1 H) 4.37 (td, *J*=10.2, 6.8 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.59 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.84 - 5.89 (m, 2 H) 6.46 (d, *J*=8.5 Hz, 1 H) 6.99 - 7.05 (m, 2 H) 7.14 (d, *J*=2.2 Hz, 1 H) 7.31 (d, *J*=8.2 Hz, 1 H) 7.34 (d, *J*=8.2 Hz, 1 H) 8.02 (s, 1 H)

LC/MS (method LC-A): R_t 3.39 min, MH⁺ 567

[α]_D²⁰: +31.1° (c 0.2736, DMF)

25 Chiral SFC (method SFC-E): R_t 2.02 min, MH⁺ 567, chiral purity 100%.

Enantiomer 5B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.09 - 3.25 (m, 2 H) 3.60 - 3.67 (m, 5 H) 3.78
30 - 3.87 (m, 2 H) 3.90 (s, 3 H) 4.04 (td, *J*=10.2, 6.9 Hz, 1 H) 4.37 (td, *J*=10.2, 6.8 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.59 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=1.9 Hz, 1 H) 5.87 (br s, 2 H) 6.47 (d, *J*=8.5 Hz, 1 H) 6.99 - 7.05 (m, 2 H) 7.14 (d, *J*=1.9 Hz, 1 H) 7.31 (d, *J*=8.2 Hz, 1 H) 7.34 (d, *J*=8.2 Hz, 1 H) 8.02 (s, 1 H)

LC/MS (method LC-A): R_t 3.39 min, MH⁺ 567

[α]_D²⁰: -31.0° (c 0.2773, DMF)

35 Chiral SFC (method SFC-E): R_t 3.00 min, MH⁺ 567, chiral purity 100%.

Example 6.1 : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **6**)



5 Synthesis of Compound **6**:

HATU (1.54 g, 4.06 mmol) was added to a mixture of 6-(trifluoromethoxy)indoline [CAS 953906-76-8] (550 mg, 2.70 mmol), 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **2e** (1 g, 2.70 mmol) and diisopropylethylamine (1.34 mL, 8.11 mmol) in DMF (30 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with water. The precipitate was filtered off, and washed with water. The solid was dissolved in EtOAc, washed with a 10% solution of K₂CO₃ in water and then with brine. The organic layer was dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99.5/0.5) to afford 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **6**, 500 mg). An analytical sample of Compound **6** was obtained by crystallized from diisopropyl ether.


20 Compound **6**:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.14 - 3.22 (m, 2 H) 3.58 - 3.68 (m, 5 H) 3.80 - 3.90 (m, 2 H) 4.05 - 4.15 (m, 1 H) 4.38 - 4.47 (m, 1 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.70 (d, *J*=9.1 Hz, 1 H) 5.79 (t, *J*=1.9 Hz, 1 H) 5.93 (d, *J*=1.9 Hz, 2 H) 6.63 (d, *J*=9.1 Hz, 1 H) 7.03 (dd, *J*=8.2, 1.6 Hz, 1 H) 7.31 - 7.37 (m, 2 H) 7.42 - 7.51 (m, 2 H) 8.02 (s, 1 H)

LC/MS (method LC-A): R_t 3.39 min, MH⁺ 555

Melting point: 166°C

Example 6.2 : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **6**) and chiral separation into Enantiomers **6A** and **6B**.



Synthesis of intermediate **6a**:

HATU (7.02 g, 18.5 mmol) was added to a mixture of 6-(trifluoromethoxy)indoline [CAS 953906-76-8] (2.5 g, 12.31 mmol), 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (2.32 g, 12.3 mmol) and diisopropylethylamine (6.1 mL, 36.9 mmol) in DMF (100 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with water and the precipitate was filtered off and washed with water. The residue was taken up with EtOAc and the organic layer was washed with a 10% solution of K₂CO₃ in water, washed with brine, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The crude product was crystallized from diisopropyl ether to give 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **6a** (4 g).

Synthesis of intermediate **6b**:

At -78°C, under a N₂ flow, LiHMDS 1M in THF (21.4 mL, 21.4 mmol) was added dropwise to a mixture of 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **6a** (4 g, 10.7 mmol) in THF (60 mL). The mixture was stirred for 15 min at -78°C and a solution of NBS (2.1 g, 11.8 mmol) in THF (40 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched with a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure to

give 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **6b** (4.8 g). The compound was used as such in the next step.

Synthesis of Compound 6 and chiral separation into Enantiomers 6A and 6B:

5 A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone **6b** (4.8 g, 10.6 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (2.3 g, 12.7 mmol) and diisopropylethylamine (2.2 mL, 12.7 mmol) in CH₃CN (200 mL) was stirred at 70°C for 72h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl and
10 water. The organic phase was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were combined and evaporated to dryness to give racemic 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-
15 (6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **6**, 3 g) after crystallization from CH₃CN/diisopropyl ether. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel[®] OD-H 5 μm 250 x 30 mm, Mobile phase: 60% CO₂, 40% EtOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (1.45 g) was solidified by trituration with MeOH/water to give Enantiomer **6A** (1.409 g). The
20 second eluted enantiomer (1.41 g) was solidified by trituration with MeOH/water to give Enantiomer **6B** (1.37 g).

Enantiomer 6A:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.13 - 3.21 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.78
25 - 3.91 (m, 2 H) 4.04 - 4.14 (m, 1 H) 4.37 - 4.48 (m, 1 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.69 (d, *J*=9.1 Hz, 1 H) 5.80 (s, 1 H) 5.93 (d, *J*=1.5 Hz, 2 H) 6.60 (br d, *J*=9.1 Hz, 1 H) 7.02 (br d, *J*=8.1 Hz, 1 H) 7.30 - 7.38 (m, 2 H) 7.41 - 7.51 (m, 2 H) 8.02 (s, 1 H)
LC/MS (method LC-A): R_t 3.41 min, MH⁺ 555
[α]_D²⁰: -25.9° (c 0.27, DMF)
30 Chiral SFC (method SFC-F): R_t 4.08 min, MH⁺ 555, chiral purity 100%.

Enantiomer 6B:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.13 - 3.20 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.79
- 3.91 (m, 2 H) 4.04 - 4.14 (m, 1 H) 4.38 - 4.49 (m, 1 H) 4.77 (t, *J*=5.6 Hz, 1 H)
35 5.69 (d, *J*=9.1 Hz, 1 H) 5.80 (s, 1 H) 5.93 (d, *J*=2.0 Hz, 2 H) 6.60 (d, *J*=8.6 Hz, 1 H) 7.02 (br d, *J*=9.1 Hz, 1 H) 7.29 - 7.38 (m, 2 H) 7.42 - 7.50 (m, 2 H) 8.02 (s, 1 H)
LC/MS (method LC-A): R_t 3.41 min, MH⁺ 555
[α]_D²⁰: +23.3° (c 0.27, DMF)

Chiral SFC (method SFC-F): R_t 2.25 min, MH^+ 555, chiral purity 99.42%.

Example 7.1 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound 7)



Synthesis of intermediate 7a:

A mixture of 1-methoxy-4-nitro-2-(trifluoromethyl)benzene [CAS 654-76-2] (24.5 g, 110.8 mmol) and 4-chlorophenoxyacetonitrile [CAS 3598-13-8] (20.4 g, 121.9 mmol) in DMF (100 mL) was added dropwise over 30 min to a stirred solution of *t*BuOK (27.4 g, 243.7 mmol) in DMF (100 mL) at -10°C . After addition, the purple solution was maintained at -10°C for 1 h. Ice-water (500 mL) and 6N HCl (500 mL) were added and the precipitate was filtered off, washed with water and dried under vacuum to afford 2-(5-methoxy-2-nitro-4-(trifluoromethyl)phenyl)acetonitrile **7a** (40.4 g) which was used as such in the next step.

Synthesis of intermediate 7b:

A solution of 2-(5-methoxy-2-nitro-4-(trifluoromethyl)phenyl)acetonitrile **7a** (26 g, 99.9 mmol) in ethanol/water (9/1) (500 mL) and AcOH (5.2 mL) was hydrogenated for 1 h under pressure (3.5 Bar) with 10% Pd/C (15.3 g) as the catalyst. The reaction mixture was filtered through a pad of celite® and the filter cake was washed with a mixture of CH_2Cl_2 and CH_3OH . The combined filtrates were concentrated under reduced pressure. The crude residue was filtered through a

pad of silica (60-200 μm) using heptane/EtOAc 80/20 as the eluent. The fractions containing the expected compound were combined and the solvent was concentrated under reduced pressure to give 5-methoxy-6-(trifluoromethyl)-1*H*-indole **7b** (15.6 g).

5

Synthesis of intermediate 7c:

At 0°C, BH_3 -Pyridine (23.5 mL, 232.4 mmol) was added dropwise to a solution of 5-methoxy-6-(trifluoromethyl)-1*H*-indole **7b** (10 g, 46.5 mmol) in EtOH (60 mL). 6N HCl (140 mL) was slowly added while maintaining the reaction temperature below 10°C. The mixture was stirred at 0°C for 2 h. Water (200 mL) was added and the mixture was basified until pH 8-9 with a concentrated solution of NaOH in water, while keeping the reaction temperature below 20°C. The precipitate was filtered off, washed with water (twice) and co-evaporated under reduced pressure with toluene to give 5-methoxy-6-(trifluoromethyl)indoline **7c** (9 g).

15

Synthesis of intermediate 7d:

HATU (0.84 g, 2.21 mmol) was added to a mixture of 5-methoxy-6-(trifluoromethyl)indoline **7c** (320 mg, 1.47 mmol), 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)acetic acid **3c** (631 mg, 1.55 mmol) and diisopropylethylamine (731 μL , 4.42 mmol) in DMF (18 mL). The reaction mixture was stirred at room temperature for 12 h. The reaction was diluted with water and EtOAc. The organic layer was separated, washed with a 10% solution of K_2CO_3 in water, dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (15-40 μm , 80 g, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99.5/0.5) to give 2-((3-(2-(*tert*-butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone **7d** (839 mg).

25

Synthesis of Compound 7:

2-((3-(2-(*tert*-Butoxy)ethoxy)-5-methoxyphenyl)amino)-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone **7d** (1.15 g, 1.89 mmol) was added to 4M HCl in dioxane (20 mL) and the mixture was stirred at room temperature for 18 h. The mixture was diluted with water and was basified with K_2CO_3 . The aqueous layer was extracted with EtOAc. The organic layer was washed with water, dried over MgSO_4 , filtered, and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel (15-40 μm , 40 g, $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 99/1/0.1). The pure fractions were combined and evaporated to dryness to afford 2-(4-chlorophenyl)-2-

35

((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **7**, 915 mg). An analytical sample of Compound **7** was obtained by crystallized from CH₃CN.


5 Compound 7:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.15 - 3.29 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.79 - 3.90 (m, 5 H) 3.96 - 4.07 (m, 1 H) 4.51 (td, *J*=10.4, 6.0 Hz, 1 H) 4.78 (t, *J*=5.0 Hz, 1 H) 5.54 (d, *J*=8.5 Hz, 1 H) 5.76 (s, 1 H) 5.95 (s, 2 H) 6.40 (br d, *J*=8.5 Hz, 1 H) 7.23 (s, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.56 (d, *J*=8.5 Hz, 2 H) 8.34 (s, 1 H)

10 LC/MS (method LC-A): R_t 3.21 min, MH⁺ 551

Melting point: 188°C

Example 7.2 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **7**) and chiral separation into Enantiomers **7A** and **7B**.



Synthesis of Compound 7 and chiral separation into Enantiomers 7A and 7B:

20 Under N₂ flow, at 5°C, propylphosphonic anhydride (4.15 mL, 6.91 mmol) was added dropwise to a mixture of 5-methoxy-6-(trifluoromethyl)indoline **7c** (1 g, 4.60 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **3f** (1.94 g, 5.53 mmol) and diisopropylethylamine (1.67 mL, 10.1 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 7 h. Water was

25 added and the mixture was extracted with EtOAc. The organic layer was washed with a 10% solution of K₂CO₃ in water, and then with water. The organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was carried out by flash chromatography on silica gel, (15-40 μm, 90 g, CH₂Cl₂/MeOH 99/1). The pure fractions were combined and

30 evaporated to dryness, to give 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **7**, 2.17 g) as a racemic mixture. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IA 5 μm 250 x 20 mm,

Mobile phase: 45% CO₂, 55% iPrOH (+ 0.3% iPrNH₂). The first eluted enantiomer (980 mg) was crystallized from MeOH to afford Enantiomer **7A** (711 mg). The second eluted enantiomer (1.08 g) was further purified by flash chromatography on silica gel (15-40 μm, 40 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were
 5 combined and evaporated to dryness (950 mg) to afford, after crystallization from MeOH, Enantiomer **7B** (770 mg).


Enantiomer 7A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.15 - 3.31 (m, 2 H) 3.60 - 3.68 (m, 5 H)
 10 3.79-3.90 (m, 5 H) 3.95 - 4.04 (m, 1 H) 4.51 (td, *J*=10.4, 6.3 Hz, 1 H) 4.80 (t, *J*=5.4 Hz, 1 H) 5.54 (d, *J*=8.5 Hz, 1 H) 5.76 (s, 1 H) 5.95 (s, 2 H) 6.41 (d, *J*=8.5 Hz, 1 H) 7.24 (s, 1 H) 7.44 (d, *J*=8.2 Hz, 2 H) 7.56 (d, *J*=8.5 Hz, 2 H) 8.34 (s, 1 H)
 LC/MS (method LC-A): R_t 3.22 min, MH⁺ 551
 [α]_{D20}: -45.2° (c 0.314, DMF)
 15 Chiral SFC (method SFC-G): R_t 2.35 min, MH⁺ 551, chiral purity 100%.
 Melting point: 112°C

Enantiomer 7B:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.15 - 3.31 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.79
 20 - 3.90 (m, 5 H) 3.95 - 4.05 (m, 1 H) 4.51 (td, *J*=10.3, 6.5 Hz, 1 H) 4.80 (br t, *J*=5.0 Hz, 1 H) 5.54 (d, *J*=8.8 Hz, 1 H) 5.76 (s, 1 H) 5.95 (s, 2 H) 6.41 (d, *J*=8.8 Hz, 1 H) 7.24 (s, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.56 (d, *J*=8.5 Hz, 2 H) 8.34 (s, 1 H)
 LC/MS (method LC-A): R_t 3.21 min, MH⁺ 551
 [α]_{D20}: +43.8° (c 0.27, DMF)
 25 Chiral SFC (method SFC-G): R_t 3.84 min, MH⁺ 551, chiral purity 100%.
 Melting point: 112°C

Example 8.1 : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone
 30 (Compound **8**).



Synthesis of Compound 8:

HATU (308 mg, 0.81 mmol) was added to a mixture of 5-methoxy-6-(trifluoromethyl)indoline **7c** (117 mg, 0.54 mmol), 2-(4-chloro-2-fluorophenyl)-2-((3-
5 (2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **2e** (200 mg, 0.54 mmol) and diisopropylethylamine (0.267 mL, 1.61 mmol) in DMF (10 mL). The reaction mixture was stirred at room temperature for 12 h. The reaction was diluted with water, causing precipitation. The precipitate was filtered off and washed with water. The solid was dissolved in EtOAc. The organic layer was washed with a
10 10% solution of K₂CO₃ in water and with brine, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). The residue was crystallized from Et₂O/diisopropyl ether to give 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-
15 (trifluoromethyl)indolin-1-yl)ethanone (Compound **8**, 35 mg).

Compound 8:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.19 - 3.28 (m, 2 H) 3.59 - 3.69 (m, 5 H) 3.85
(m, 5 H) 3.99 - 4.08 (m, 1 H) 4.37 - 4.47 (m, 1 H) 4.80 (t, *J*=5.4 Hz, 1 H) 5.68 (br d,
20 *J*=9.1 Hz, 1 H) 5.79 (s, 1 H) 5.93 (s, 2 H) 6.58 (br d, *J*=9.1 Hz, 1 H) 7.26 (s, 1 H)
7.33 (br d, *J*=7.6 Hz, 1 H) 7.42 - 7.52 (m, 2 H) 8.33 (s, 1 H)

LC/MS (method LC-A): R_t 3.27 min, MH⁺ 569

Melting point: 176°C

25 **Example 8.2** : synthesis of 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **8**) and chiral separation into Enantiomers **8A** and **8B**.

-37-



Synthesis of intermediate **8a**:

HATU (2.9 g, 7.6 mmol) was added to a mixture of 5-methoxy-6-(trifluoromethyl)-indoline **7c** (1.1 g, 5.06 mmol), 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (1.05 g, 5.57 mmol) and diisopropylethylamine (2.51 mL, 15.2 mmol) in DMF (30 mL). The reaction mixture was stirred at room temperature for 12h. The mixture was diluted with water, causing precipitation. The precipitate was filtered off and washed with water. The residue was taken up with EtOAc and the organic solution was washed with a 10% solution of K₂CO₃ in water and then with brine. The organic solution was dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (15-40 μm, 80 g, heptane/EtOAc 90/10 to 60/40). The pure fractions were combined and the solvent was evaporated under reduced pressure to give 2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)-indolin-1-yl)ethanone **8a** (1.8 g).

Synthesis of intermediate **8b**:

At -78°C, under a N₂ flow, LiHMDS 1M in THF (9.3 mL, 9.3 mmol) was added dropwise to a mixture of 2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone **8a** (1.8 g, 4.65 mmol) in THF (25 mL). TMSCl (0.7 mL, 0.86 mmol) was added dropwise. The mixture was stirred for 15 min at -78°C and a solution of NBS (1 g, 5.57 mmol) in THF (15 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched by the addition of a saturated aqueous solution of NH₄Cl. The mixture was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and the solvent was evaporated under

reduced pressure to give 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone **8b** (2.1 g). The compound was used as such in the next step.

5 **Synthesis of Compound 8 and chiral separation into Enantiomers 8A and 8B:**

A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone **8b** (2.1 g, 4.5 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.99 g, 5.4 mmol) and diisopropylethylamine (1.16 mL, 6.75 mmol) in CH₃CN (80 mL) was stirred at 70°C for 72 h. The mixture was
10 concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl and water. The organic phase was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂). The pure fractions were combined and evaporated to dryness to give racemic 2-(4-chloro-2-fluorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-
15 (trifluoromethyl)indolin-1-yl)ethanone (Compound **8**, 850 mg) after crystallization from CH₃CN. This fraction was combined with another batch (total amount: 1.3 g). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak® IA 5 μm 250 x 20 mm, Mobile phase: 70% CO₂, 30% EtOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (680 mg) was solidified by trituration with
20 CH₃CN to give Enantiomer **8A** (590 mg). The second eluted enantiomer (630 mg) was solidified by trituration with CH₃CN to give Enantiomer **8B** (569 mg).

Enantiomer 8A:

25 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.19 - 3.27 (m, 2 H) 3.59 - 3.69 (m, 5 H) 3.78 - 3.91 (m, 5 H) 3.98 - 4.08 (m, 1 H) 4.35 - 4.47 (m, 1 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.67 (d, *J*=9.1 Hz, 1 H) 5.79 (t, *J*=1.8 Hz, 1 H) 5.93 (d, *J*=2.0 Hz, 2 H) 6.55 (d, *J*=9.1 Hz, 1 H) 7.25 (s, 1 H) 7.31 (dd, *J*=8.3, 1.8 Hz, 1 H) 7.42 - 7.50 (m, 2 H) 8.32 (s, 1 H)

30 LC/MS (method LC-A): R_t 3.26 min, MH⁺ 569

[α]_D²⁰: -28.9° (c 0.225, DMF)

Chiral SFC (method SFC-H): R_t 4.51 min, MH⁺ 569, chiral purity 100%.

Enantiomer 8B:

35 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.19- 3.27 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.80 - 3.90 (m, 5 H) 3.98 - 4.09 (m, 1 H) 4.35 - 4.47 (m, 1 H) 4.77 (t, *J*=5.3 Hz, 1 H) 5.67 (d, *J*=9.1 Hz, 1 H) 5.79 (t, *J*=1.8 Hz, 1 H) 5.93 (d, *J*=1.5 Hz, 2 H) 6.54 (d,

$J=8.6$ Hz, 1 H) 7.25 (s, 1 H) 7.31 (dd, $J=8.6, 2.0$ Hz, 1 H) 7.42 - 7.50 (m, 2 H) 8.32 (s, 1 H)


LC/MS (method LC-A): R_t 3.26 min, MH^+ 569

$[\alpha]_D^{20}$: +25.7° (c 0.2333, DMF)

5 Chiral SFC (method SFC-H): R_t 5.81 min, MH^+ 569, chiral purity 100%.

Example 9 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(4-methyl-6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **9**) and chiral separation into Enantiomers **9A** and **9B**.

10



Synthesis of intermediate **9a**:

To a solution of 2-methyl-4-(trifluoromethoxy)aniline [CAS 86256-59-9] (10.0 g, 52.3 mmol) in dioxane (20 mL) was added trifluoroacetic anhydride (8 mL, 57.2 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc and 1N HCl. The phases were separated. The organic phase was washed with a saturated solution of NaHCO₃ in water, H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford 14.7 g of 2,2,2-trifluoro-N-(2-methyl-4-(trifluoromethoxy)phenyl)acetamide **9a** as a white powder. The compound was used in the next step without further purification.

Synthesis of intermediate 9c:

To acetic anhydride (11.4 mL, 61.1 mmol), cooled at 0°C was added dropwise 70% nitric acid (3.9 mL). 2,2,2-Trifluoro-*N*-(2-methyl-4-(trifluoromethoxy)phenyl)-acetamide **9a** (5 g, 17.4 mmol) was added portionwise and the reaction mixture was heated at 55°C for 12 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc and washed with H₂O. The organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was dissolved in methanol (46 mL). 2M K₂CO₃ (23 mL, 46 mmol) was added and the reaction mixture was heated at 70°C for 4 h. More 2M K₂CO₃ (10 mL, 20 mmol) was added and the reaction mixture was heated at 70°C for 12 h. The reaction mixture was partially concentrated under reduced pressure to remove methanol. The residue was extracted with EtOAc. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (20% to 50%) in heptane to afford 3.6 g of 2-methyl-6-nitro-4-(trifluoromethoxy)aniline **9c** as a yellow solid.

Synthesis of intermediate 9d:

To a solution of 2-methyl-6-nitro-4-(trifluoromethoxy)aniline **9c** (1.8 g, 7.69 mmol) in acetic acid (10.9 mL) was added dropwise a solution of sodium nitrite (0.806 g, 11.7 mmol) in H₂SO₄/H₂O (2 mL, 1/1). The reaction mixture was stirred at room temperature for 30 min. H₂O (22 mL) and urea (0.802 g, 13.4 mmol) were added. After 10 min at room temperature, a solution of potassium iodide (1.7 g, 10.2 mmol) in H₂O (11 mL) was added dropwise. The reaction mixture was stirred at room temperature for 30 min. The yellow solid was filtered off, washed with H₂O and dried to give 2.4 g of 2-iodo-1-methyl-3-nitro-5-(trifluoromethoxy)benzene **9d**.

Synthesis of intermediate 9e:

To a solution of 2-iodo-1-methyl-3-nitro-5-(trifluoromethoxy)benzene **9d** (3.5 g, 10.0 mmol) in EtOH (30 mL) was added a solution of NH₄Cl (2.7 g, 49.9 mmol) in H₂O (30 mL). The reaction mixture was heated at 50°C. Iron (2.6 g, 46.9 mmol) was added and the reaction mixture was heated under reflux for 40 min. After cooling to room temperature, the reaction mixture was filtered through celite®. The solids were washed with EtOH. The filtrate was partially concentrated under reduced pressure to remove EtOH. The residue was partitioned between EtOAc and a saturated solution of NaHCO₃ in water. The phases were separated. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and

concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (0% to 25%) in heptane to afford 2.9 g of 2-iodo-3-methyl-5-(trifluoromethoxy)aniline **9e** as a yellow oil.

5 **Synthesis of intermediate 9f:**

A solution of 2-iodo-3-methyl-5-(trifluoromethoxy)aniline **9e** (2.9 g, 9.1 mmol) in triethylamine (23 mL) was degassed with argon for 15 min.

Dichlorobis(triphenylphosphine)palladium(II) (0.327 g, 0.47 mmol), copper(I) iodide (0.164 g, 0.86 mmol) and trimethylsilylacetylene (1.8 mL, 13.1 mmol) were added.

10 The reaction mixture was heated at 65°C for 12 h. After cooling to room temperature, the reaction mixture was diluted with H₂O and extracted with EtOAc (3x). The organic phases were combined, washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (0% to
15 20%) in heptane to afford 2.6 g of 3-methyl-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **9f** as an orange oil.

Synthesis of intermediate 9g:

To a solution of 3-methyl-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **9f**
20 (2.7 g, 9.3 mmol) in NMP (27 mL) was added *t*BuOK (3.1 g, 27.8 mmol). The reaction mixture was heated at 80°C for 4 h. After cooling to room temperature, the reaction mixture was diluted with H₂O and extracted with EtOAc (2x). The organic phases were combined, washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by
25 flash chromatography on silica gel using a gradient of EtOAc (0% to 20%) in heptane to afford 1.7 g of 4-methyl-6-(trifluoromethoxy)-1*H*-indole **9g** as an orange oil.

Synthesis of intermediate 9h:

30 At 0°C, BH₃-Pyridine (1.2 mL, 11.6 mmol) was added dropwise to a solution of 4-methyl-6-(trifluoromethoxy)-1*H*-indole **9g** (0.5 g, 2.32 mmol) in EtOH (3 mL). 6N HCl (6 mL) was slowly added dropwise while maintaining the reaction temperature below 10°C. The mixture was stirred at 0°C for 3 h. Water (12 mL) was added and the mixture was basified until pH 8-9 with a concentrated solution of NaOH in
35 water (the reaction temperature was kept below 20°C). The mixture was extracted with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Toluene was added and

the solution was concentrated under reduced pressure to give 450 mg of 4-methyl-6-(trifluoromethoxy)indoline **9h**.

Synthesis of Compound 9 and chiral separation into Enantiomers 9A and 9B:

5 Under N₂ flow at 5°C, propylphosphonic anhydride (1.87 mL, 3.11 mmol) was added dropwise to a mixture of 4-methyl-6-(trifluoromethoxy)indoline **9h** (450 mg, 2.07 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)-amino)acetic acid **3f** (729 mg, 2.07 mmol) and diisopropylethylamine (753 µL, 4.56 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 7 h.

10 Water was added and the mixture was extracted with EtOAc. The organic layer was washed with a solution of K₂CO₃ 10% in water, then with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure.

Purification was performed by flash chromatography on silica gel, (15-40 µm, 24 g, CH₂Cl₂/MeOH 99.5/0.5). The pure fractions were combined and evaporated to

15 dryness, to give racemic 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(4-methyl-6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **9**, 411 mg). The enantiomers of Compound **9** were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IA 5 µm 250 x 20 mm, Mobile phase: 50% CO₂, 50% iPrOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (180 mg) was

20 solidified from heptane/diisopropyl ether to afford Enantiomer **9A** (121 mg). The second eluted enantiomer (180 mg) was solidified from heptane/diisopropyl ether to afford Enantiomer **9B** (132 mg).

Enantiomer 9A:

25 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.20 (s, 3 H) 2.98 - 3.17 (m, 2 H) 3.59 - 3.69 (m, 5 H) 3.79 - 3.90 (m, 2 H) 4.05 (td, *J*=10.6, 6.9 Hz, 1 H) 4.52 (td, *J*=10.5, 6.1 Hz, 1 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.55 (d, *J*=8.8 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=1.9 Hz, 2 H) 6.43 (d, *J*=8.8 Hz, 1 H) 6.88 (s, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.55 (d, *J*=8.5 Hz, 2 H) 7.88 (s, 1 H)

30 LC/MS (method LC-A): R_t 3.48 min, MH⁺ 551
[α]_D²⁰: -40.6° (c 0.2067, DMF)
Chiral SFC (method SFC-G): R_t 2.08 min, MH⁺ 551, chiral purity 100%.

Enantiomer 9B:

35 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.20 (s, 3 H) 2.98 - 3.17 (m, 2 H) 3.59 - 3.67 (m, 5 H) 3.79 - 3.90 (m, 2 H) 4.05 (td, *J*=10.6, 6.9 Hz, 1 H) 4.52 (td, *J*=10.5, 6.1 Hz, 1 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.55 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=1.9 Hz, 1 H) 5.94

(d, $J=1.9$ Hz, 2 H) 6.43 (d, $J=8.8$ Hz, 1 H) 6.88 (s, 1 H) 7.44 (d, $J=8.5$ Hz, 2 H) 7.55 (d, $J=8.5$ Hz, 2 H) 7.88 (s, 1 H)


LC/MS (method LC-A): R_t 3.48 min, MH^+ 551

$[\alpha]_D^{20} +42.6^\circ$ (c 0.2392, DMF)

5 Chiral SFC (method SFC-G): R_t 3.34 min, MH^+ 551, chiral purity 99.7%.

Example 10 : synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(4-methyl-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **10**) and chiral separation into Enantiomers **10A** and **10B**.

10



Synthesis of intermediate 10a:

15 Pd/C (10%) (1.18 g) was added to a solution of 1-benzyl-4-methyl-6-(trifluoromethyl)indoline [CAS 1156512-79-6] (11.8 g, 40.5 mmol) in AcOH (11.8 mL) and MeOH (118 mL). The reaction was stirred at room temperature for 12 h under H_2 atmosphere. The mixture was filtered through a pad of celite® and concentrated under reduced pressure. The residue was taken up with CH_2Cl_2 , washed with water, brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (heptane/EtOAc 20 9/1). The pure fractions were combined and the solvent was evaporated to dryness to give 8.2 g of 4-methyl-6-(trifluoromethyl)indoline **10a**.

Synthesis of Compound 10 and chiral separation into Enantiomers 10A and 10B:

25 A mixture of 4-methyl-6-(trifluoromethyl)indoline **10a** (515 mg, 2.56 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **3f** (900 mg, 2.56 mmol), diisopropylethylamine (1.27 mL, 7.67 mmol) and HATU (1.46 g, 3.84 mmol) in DMF (7 mL) was stirred at room temperature for 18 h. Water was added and the mixture was extracted with EtOAc. The organic layer

was washed with water (several times), dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was performed by flash chromatography on silica gel, (15-40 μm, 40 g, heptane/EtOAc 50/50). This fraction was combined with another batch (total amount: 640 mg) and further
5 purified by reverse phase chromatography (Stationary phase: X-Bridge® C18 10 μm 30 x 150 mm, Mobile phase: gradient from 60% NH₄HCO₃ 0.2%, 40% CH₃CN to 0% NH₄HCO₃ 0.2%, 100% CH₃CN). The pure fractions were combined and evaporated to dryness, to give racemic 2-(4-chlorophenyl)-2-((3-(2-hydroxy-ethoxy)-5-methoxyphenyl)amino)-1-(4-methyl-6-(trifluoromethyl)indolin-1-yl)-
10 ethanone (Compound **10**, 425 mg). The enantiomers of Compound **10** were separated via Preparative Chiral SFC (Stationary phase: Chiralpak® IA 5 μm 250 x 20 mm, Mobile phase: 50% CO₂, 50% EtOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (180 mg) was solidified from heptane/diisopropyl ether to afford Enantiomer **10A** (145 mg). The second eluted enantiomer (170 mg) was solidified
15 from heptane/diisopropyl ether to afford Enantiomer **10B** (113 mg).

Enantiomer 10A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.25 (s, 3 H) 3.05 - 3.24 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.80 - 3.90 (m, 2 H) 4.04 (td, *J*=10.6, 6.9 Hz, 1 H) 4.54 (td, *J*=10.5, 6.1
20 Hz, 1 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.57 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.95 (d, *J*=0.9 Hz, 2 H) 6.42 (d, *J*=8.5 Hz, 1 H) 7.25 (s, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.56 (d, *J*=8.5 Hz, 2 H) 8.23 (s, 1 H)

LC/MS (method LC-A): R_t 3.43 min, MH⁺ 535

[α]_D²⁰: -46.2° (c 0.2275, DMF)

25 Chiral SFC (method SFC-I): R_t 2.26 min, MH⁺ 535, chiral purity 100%.

Enantiomer 10B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.25 (s, 3 H) 3.05 - 3.24 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.80 - 3.91 (m, 2 H) 4.04 (td, *J*=10.5, 7.1 Hz, 1 H) 4.54 (td, *J*=10.4, 6.3
30 Hz, 1 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.57 (d, *J*=8.5 Hz, 1 H) 5.76 (t, *J*=2.0 Hz, 1 H) 5.95 (d, *J*=0.9 Hz, 2 H) 6.42 (d, *J*=8.8 Hz, 1 H) 7.25 (s, 1 H) 7.44 (d, *J*=8.5 Hz, 2 H) 7.56 (d, *J*=8.2 Hz, 2 H) 8.23 (s, 1 H)

LC/MS (method LC-A): R_t 3.43 min, MH⁺ 535

[α]_D²⁰: +43.0° (c 0.2092, DMF)

35 Chiral SFC (method SFC-I): R_t 3.61 min, MH⁺ 535, chiral purity 100%.

Example 11 : synthesis of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **11**) and chiral separation into Enantiomers **11A** and **11B**.



5

Synthesis of intermediate **11a**:

At -78°C, under a N₂ flow, LiHMDS 1.5 M in THF (6.2 mL, 9.32 mmol) was added dropwise to a mixture of methyl 2-(4-chloro-2-methoxyphenyl)acetate [CAS 193290-23-2] (1 g, 4.66 mmol) in THF (30 mL). A solution of TMSCl (0.95 mL, 7.45 mmol) in THF (10 mL) was added dropwise. The mixture was stirred for 15 min at -78°C and NBS (0.912 g, 5.13 mmol) in THF (10 mL) was added dropwise. After stirring for 2 h at -78°C, the reaction was quenched with a saturated solution of NH₄Cl. The mixture was extracted with EtOAc, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure to give methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate **11a** (1.4 g). The compound was used as such in the next step.

15

Synthesis of intermediate **11b**:

A mixture of methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate **11a** (0.5 g, 1.71 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (328 mg, 1.79 mmol), trimethylamine (355 μL, 2.56 mmol) in CH₃CN (10 mL) was stirred at

20

50°C for 12 h. The mixture was diluted with EtOAc and washed with water. The organic phase was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μm, 40 g, CH₂Cl₂/MeOH 99/1). The pure fractions were combined and evaporated to dryness to give methyl 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **11b** (510 mg).

Synthesis of intermediate **11c**:

10 Methyl 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetate **11b** (1.2 g, 3.03 mmol) and LiOH (382 mg, 9.10 mmol) in THF/water (1/1) (20 mL) was stirred at room temperature for 1 h. The mixture was diluted with water. The aqueous layer was slowly acidified with 3N HCl and extracted with EtOAc. The combined organic layers were dried over MgSO₄,
15 filtered and the solvent was evaporated under reduced pressure to give 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **11c** (1.12 g). The compound was used as such in the next step.

Synthesis of Compound **11** and chiral separation into Enantiomers **11A** and **11B**:

20 HATU (0.692 g, 1.82 mmol) was added to a mixture of 5-methoxy-6-(trifluoromethyl)indoline **7c** (264 mg, 1.21 mmol), 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **11c** (520 mg, 1.36 mmol) and diisopropylethylamine (0.602 mL, 3.64 mmol) in DMF (14 mL). The resulting
25 mixture was stirred at room temperature for 12 h. The mixture was diluted with water and EtOAc. The organic layer was separated, washed with a 10% solution of K₂CO₃ in water and then with brine. The organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel (15-40 μm, 40 g,
30 CH₂Cl₂/MeOH 99.5/0.5). The pure fraction were combined and evaporated to dryness to afford racemic 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone (Compound **11**, 398 mg). This batch was combined with another batch (total amount: 535 mg). The enantiomers were separated via Preparative Chiral SFC
35 (Stationary phase: Chiralpak[®] IA 5 μm 250 x 20 mm, Mobile phase: 70% CO₂, 30% iPrOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (240 mg) was crystallized from CH₃CN/diisopropyl ether to give Enantiomer **11A** (194 mg). The

second eluted enantiomer (240 mg) was crystallized from CH₃CN/diisopropyl ether to give Enantiomer **11B** (189 mg).

Compound 11:

- 5 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.19 - 3.29 (m, 2 H) 3.59 - 3.69 (m, 5 H) 3.78 - 3.88 (m, 5 H) 3.91 (s, 3 H) 3.95 - 4.04 (m, 1 H) 4.31 - 4.41 (m, 1 H) 4.80 (t, *J*=5.4 Hz, 1 H) 5.59 (br d, *J*=8.5 Hz, 1 H) 5.73 - 5.78 (m, 1 H) 5.87 (br s, 2 H) 6.41 (br d, *J*=8.5 Hz, 1 H) 7.03 (dd, *J*=8.2, 1.3 Hz, 1 H) 7.15 (d, *J*=1.3 Hz, 1 H) 7.25 (s, 1 H) 7.33 (d, *J*=8.2 Hz, 1 H) 8.33 (s, 1 H)
- 10 LC/MS (method LC-A): R_t 3.22 min, MH⁺ 581
Melting point: 224°C


Enantiomer 11A:

- 15 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.16 - 3.30 (m, 2 H) 3.60 - 3.68 (m, 5 H) 3.77 - 3.88 (m, 5 H) 3.90 (s, 3 H) 3.99 (td, *J*=10.2, 7.3 Hz, 1 H) 4.35 (td, *J*=10.2, 6.6 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.58 (d, *J*=8.5 Hz, 1 H) 5.73 - 5.78 (m, 1 H) 5.87 (s, 2 H) 6.41 (d, *J*=8.8 Hz, 1 H) 7.02 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.14 (d, *J*=1.9 Hz, 1 H) 7.24 (s, 1 H) 7.32 (d, *J*=8.5 Hz, 1 H) 8.33 (s, 1 H)
- LC/MS (method LC-A): R_t 3.25 min, MH⁺ 581
- 20 [α]_D20: -31.4° (c 0.274, DMF)
Chiral SFC (method SFC-H): R_t 3.60 min, MH⁺ 581, chiral purity 100%.
Melting point: 175°C

Enantiomer 11B:

- 25 ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.17 - 3.30 (m, 2 H) 3.59 - 3.68 (m, 5 H) 3.78 - 3.88 (m, 5 H) 3.91 (s, 3 H) 3.99 (td, *J*=10.2, 7.3 Hz, 1 H) 4.35 (td, *J*=10.2, 6.6 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.58 (d, *J*=8.5 Hz, 1 H) 5.73 - 5.78 (m, 1 H) 5.87 (s, 2 H) 6.41 (d, *J*=8.8 Hz, 1 H) 7.02 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.14 (d, *J*=1.9 Hz, 1 H) 7.24 (s, 1 H) 7.32 (d, *J*=8.2 Hz, 1 H) 8.33 (s, 1 H)
- 30 LC/MS (method LC-A): R_t 3.25 min, MH⁺ 581
[α]_D20: +29.4° (c 0.272, DMF)
Chiral SFC (method SFC-H): R_t 4.96 min, MH⁺ 581, chiral purity 100%.
Melting point: 175°C

Example 12 : synthesis of 2-(4-chlorophenyl)-1-(5-fluoro-6-(trifluoromethyl)indolin-1-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **12**) and chiral separation into Enantiomers **12A** and **12B**.



Synthesis of intermediate **12a**:

At 0°C, BH₃-Pyridine (10.5 mL, 103.5 mmol) was added dropwise to a solution of 5-fluoro-6-(trifluoromethyl)-1*H*-indole [CAS 1493800-10-4] (7 g, 34.5 mmol) in EtOH (45 mL). 6N HCl (105 mL) was slowly added dropwise while maintaining the reaction temperature below 10°C. The mixture was stirred at 0°C for 3 h. Water (210 mL) was added and the mixture was basified until pH 8-9 with a concentrated solution of NaOH in water (the reaction temperature was kept below 20°C). The mixture was extracted with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Toluene was added and the solution was concentrated under reduced pressure. Purification was performed by flash chromatography on silica gel, (15-40 μm, 120 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 3.5 g of 5-fluoro-6-(trifluoromethyl)indoline **12a**.

10

15

20 Synthesis of Compound **12** and chiral separation into Enantiomers **12A** and **12B**:

Under N₂ flow, at 5°C, propylphosphonic anhydride (1.76 mL, 2.93 mmol) was added dropwise to a mixture of 5-fluoro-6-(trifluoromethyl)indoline **12a** (400 mg, 1.95 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)-amino)acetic acid **3f** (823 mg, 2.34 mmol) and diisopropylethylamine (709 μL, 4.29 mmol) in DMF (30 mL). The mixture was stirred at room temperature for 5 h. Water was added and the precipitate was filtered off and washed with a 10% solution of K₂CO₃ in water. The solid was taken up with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was performed by flash

25

30

chromatography on silica gel, (15-40 μm , 40 g, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99.5/0.5). The pure fractions were combined and evaporated to dryness, to give racemic 2-(4-chlorophenyl)-1-(5-fluoro-6-(trifluoromethyl)indolin-1-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **12**, 825 mg). Crystallization from CH_3CN /diisopropyl ether afforded Compound **12** (448 mg) as a crystalline fraction. The enantiomers of Compound **12** were separated via Preparative Chiral SFC (Stationary phase: Chiralcel[®] OJ-H 5 μm 250 x 20 mm, Mobile phase: 60% CO_2 , 40% EtOH (+ 0.3% iPrNH_2)). The first eluted enantiomer (193 mg) was solidified from heptane/diisopropyl ether to give Enantiomer **12A** (164 mg). The second eluted enantiomer (190 mg) was solidified from heptane/diisopropyl ether to give Enantiomer **12B** (131 mg).

Compound 12:

^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ ppm 3.18 - 3.31 (m, 2 H) 3.62 (s, 3 H) 3.63- 3.67 (m, 2 H) 3.80 - 3.89 (m, 2 H) 4.03 (td, $J=10.3$, 7.4 Hz, 1 H) 4.54 (td, $J=10.2$, 6.3 Hz, 1 H) 4.79 (br t, $J=5.0$ Hz, 1 H) 5.57 (d, $J=8.5$ Hz, 1 H) 5.76 (s, 1 H) 5.94 (s, 2 H) 6.44 (d, $J=8.8$ Hz, 1 H) 7.42 - 7.48 (m, 3 H) 7.55 (d, $J=8.2$ Hz, 2 H) 8.39 (d, $J=6.6$ Hz, 1 H)

LC/MS (method LC-A): R_t 3.37 min, MH^+ 539

Melting point: 130°C

Enantiomer 12A:

^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ ppm 3.17 - 3.32 (m, 2 H) 3.62 (s, 3 H) 3.64 (q, $J=5.6$ Hz, 2 H) 3.79 - 3.90 (m, 2 H) 4.03 (td, $J=10.2$, 7.3 Hz, 1 H) 4.54 (td, $J=10.4$, 6.3 Hz, 1 H) 4.79 (t, $J=5.5$ Hz, 1 H) 5.57 (d, $J=8.5$ Hz, 1 H) 5.76 (s, 1 H) 5.94 (s, 2 H) 6.44 (d, $J=8.8$ Hz, 1 H) 7.41 - 7.48 (m, 3 H) 7.55 (d, $J=8.5$ Hz, 2 H) 8.39 (d, $J=6.3$ Hz, 1 H)

LC/MS (method LC-A): R_t 3.37 min, MH^+ 539

$[\alpha]_{\text{D}20}$: +50.2° (c 0.299, DMF)

Chiral SFC (method SFC-D): R_t 1.91 min, MH^+ 539, chiral purity 100%.

Enantiomer 12B:


^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ ppm 3.18 - 3.32 (m, 2 H) 3.62 (s, 3 H) 3.65 (q, $J=5.3$ Hz, 2 H) 3.78 - 3.90 (m, 2 H) 4.03 (td, $J=10.2$, 7.3 Hz, 1 H) 4.54 (td, $J=10.2$, 6.3 Hz, 1 H) 4.79 (t, $J=5.4$ Hz, 1 H) 5.57 (d, $J=8.8$ Hz, 1 H) 5.76 (s, 1 H) 5.94 (s, 2 H) 6.44 (d, $J=8.5$ Hz, 1 H) 7.41 - 7.49 (m, 3 H) 7.55 (d, $J=8.2$ Hz, 2 H) 8.39 (d, $J=6.6$ Hz, 1 H)

LC/MS (method LC-A): R_t 3.38 min, MH^+ 539

$[\alpha]_D^{20}$: -51.0° (c 0.3, DMF)

Chiral SFC (method SFC-D): R_t 3.93 min, MH^+ 539, chiral purity 99.52%.

Example 13: synthesis of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **13**) and chiral separation into Enantiomers **13A** and **13B**.



10 Synthesis of intermediate 13a:

A solution of 4-methoxy-3-(trifluoromethoxy)aniline [CAS 647855-21-8] (3.1 g, 15.0 mmol) in toluene (50 mL) was treated with *N*-bromosuccinimide (2.8 g, 15.7 mmol) at 5°C and the resulting mixture was stirred at 5-10°C for 2 h. The mixture was diluted with water and extracted with EtOAc. The combined extracts were dried over $MgSO_4$, filtered and evaporated under reduced pressure. Purification was performed by flash chromatography on silica gel (15-40 μm , 24 g, heptane/EtOAc 95/5 to 90/10) The pure fractions were combined and evaporated to dryness to give 2-bromo-4-methoxy-5-(trifluoromethoxy)aniline **13a** (2.5 g).

20 Synthesis of intermediate 13b:

A solution of 2-bromo-4-methoxy-5-(trifluoromethoxy)aniline **13a** (2.72 g, 9.51 mmol) in DMF (30 mL) was degassed with N_2 for 15 min. Dichlorobis(triphenylphosphine)palladium(II) (667 mg, 0.95 mmol), copper(I) iodide (362 mg, 1.90 mmol), triethylamine (3.96 mL, 28.53 mmol) and trimethylsilylacetylene (3.95 mL, 28.5 mmol) were added. The reaction mixture was heated at 70°C for 12 h under N_2 flow. After cooling to room temperature, the reaction

mixture was diluted with H₂O and extracted with EtOAc. The organic phases were combined, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μm, 80 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 4-methoxy-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **13b** (1.4 g).

Synthesis of intermediate **13c**:

To a solution of 4-methoxy-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **13b** (1.2 g, 3.96 mmol) in NMP (11 mL) under N₂ flow, was added *t*BuOK (1.33 g, 11.9 mmol) in one portion. The reaction mixture was heated at 80°C for 4 h, then poured out into ice/water and acidified with 3N HCl until pH 4-5. The reaction mixture was extracted with EtOAc. The organic phases were combined, washed with H₂O, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 μm, 40 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 5-methoxy-6-(trifluoromethoxy)-1*H*-indole **13c** (490 mg).

Synthesis of intermediate **13d**:

At 0°C, BH₃-Pyridine (10.5 mL, 103.82 mmol) was added dropwise to a solution of 5-methoxy-6-(trifluoromethoxy)-1*H*-indole **13c** (8 g, 34.6 mmol) in EtOH (45 mL). 6N HCl (6 mL) was slowly added dropwise while maintaining the temperature below 10°C. The mixture was stirred at 0°C for 3 h. Water (210 mL) was added and the mixture was basified until pH 8-9 with a concentrated solution of NaOH in water (the reaction temperature was kept below 20°C). The mixture was extracted with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Toluene was added and the solution was concentrated under reduced pressure to give 7.5 g of 5-methoxy-6-(trifluoromethoxy)indoline **13d**.

Synthesis of Compound **13** and chiral separation into Enantiomers **13A** and **13B**:

Under N₂ flow at 5°C, propylphosphonic anhydride (2.1 mL, 3.35 mmol) was added dropwise to a mixture of 5-methoxy-6-(trifluoromethoxy)indoline **13d** (552 mg, 2.37 mmol), 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)acetic acid **3f** (1 g, 2.84 mmol) and diisopropylethylamine (861 μL, 5.21 mmol) in DMF (40 mL). The mixture was stirred at room temperature for 5 h. Water was added and the precipitate was filtered off and washed with a 10%

solution of K₂CO₃ in water. The solid was taken up with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was performed by flash chromatography on silica gel, (15-40 μm, 40 g, CH₂Cl₂/MeOH 99.5/0.5). Pure fractions were combined and evaporated to dryness, to give, after crystallization from diisopropyl ether, racemic 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-methoxy-6-(trifluoromethoxy)indolin-1-yl)ethanone (Compound **13**, 970 mg). The enantiomers of Compound **13** were separated via Preparative Chiral SFC (Stationary phase: Chiralpak[®] IC 5 μm 250 x 30 mm, Mobile phase: 55% CO₂, 45% EtOH (+ 0.3% iPrNH₂)). The first eluted enantiomer (400 mg) was solidified from heptane/diisopropyl ether to give Enantiomer **13A** (332 mg). The second eluted enantiomer (397 mg) was solidified from heptane/diisopropyl ether to give Enantiomer **13B** (344 mg).

Compound 13:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.10 - 3.26 (m, 2 H) 3.62 (s, 3 H) 3.65 (q, *J*=5.4 Hz, 2 H) 3.81 (s, 3 H) 3.82 - 3.88 (m, 2 H) 4.03 (td, *J*=10.3, 7.1 Hz, 1 H) 4.49 (td, *J*=10.3, 6.5 Hz, 1 H) 4.80 (t, *J*=5.4 Hz, 1 H) 5.53 (d, *J*=8.8 Hz, 1 H) 5.75 (s, 1 H) 5.94 (d, *J*=1.6 Hz, 2 H) 6.45 (d, *J*=8.5 Hz, 1 H) 7.20 (s, 1 H) 7.44 (d, *J*=8.2 Hz, 2 H) 7.55 (d, *J*=8.5 Hz, 2 H) 8.06 (s, 1 H)
LC/MS (method LC-A): R_t 3.30 min, MH⁺ 567
Melting point: 165°C

Enantiomer 13A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.10 - 3.26 (m, 2 H) 3.62 (s, 3 H) 3.65 (q, *J*=5.4 Hz, 2 H) 3.81 (s, 3 H) 3.82 - 3.88 (m, 2 H) 4.03 (td, *J*=10.3, 7.1 Hz, 1 H) 4.49 (td, *J*=10.3, 6.5 Hz, 1 H) 4.80 (t, *J*=5.4 Hz, 1 H) 5.53 (d, *J*=8.8 Hz, 1 H) 5.75 (s, 1 H) 5.94 (d, *J*=1.6 Hz, 2 H) 6.45 (d, *J*=8.5 Hz, 1 H) 7.20 (s, 1 H) 7.44 (d, *J*=8.2 Hz, 2 H) 7.55 (d, *J*=8.5 Hz, 2 H) 8.06 (s, 1 H)

LC/MS (method LC-A): R_t 3.31 min, MH⁺ 567

[α]_D20: +43.2° (c 0.285, DMF)

Chiral SFC (method SFC-J): R_t 1.82 min, MH⁺ 567, chiral purity 100%.

Enantiomer 13B:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.09 - 3.26 (m, 2 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.81 (s, 3 H) 3.82 - 3.88 (m, 2 H) 4.02 (td, *J*=10.4, 6.9 Hz, 1 H) 4.48 (td, *J*=10.3, 6.1 Hz, 1 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.53 (d, *J*=8.5 Hz, 1 H) 5.75 (s, 1

H) 5.94 (d, $J=1.6$ Hz, 2 H) 6.44 (d, $J=8.5$ Hz, 1 H) 7.20 (s, 1 H) 7.43 (d, $J=8.2$ Hz, 2 H) 7.55 (d, $J=8.5$ Hz, 2 H) 8.06 (s, 1 H)








LC/MS (method LC-A): R_t 3.31 min, MH^+ 567








$[\alpha]_D^{20}$: -45.9° (c 0.301, DMF)







5 Chiral SFC (method SFC-J): R_t 3.15 min, MH^+ 567, chiral purity 98.96%.







Table : compounds prepared as described above







Compound	Structure	Optical rotation
1		racemic
1A		$[\alpha]_D^{20} = -26.5^\circ$
1B		$[\alpha]_D^{20} = +28.8^\circ$
2		racemic
2A		$[\alpha]_D^{20} = -26.4^\circ$



Compound	Structure	Optical rotation
2B		$[\alpha]_D^{20} = +27.3^\circ$
3		racemic
3A		$[\alpha]_D^{20} = +51.9^\circ$
3B		$[\alpha]_D^{20} = -51.1^\circ$
4		racemic
4A		$[\alpha]_D^{20} = +52.0^\circ$
4B		$[\alpha]_D^{20} = -51.8^\circ$

Compound	Structure	Optical rotation
5		racemic
5A		$[\alpha]_D^{20} = +31.1^\circ$
5B		$[\alpha]_D^{20} = -31.0^\circ$
6		racemic
6A		$[\alpha]_D^{20} = -25.9^\circ$
6B		$[\alpha]_D^{20} = +23.3^\circ$
7		racemic

Compound	Structure	Optical rotation
7A		$[\alpha]_D^{20} = -45.2^\circ$
7B		$[\alpha]_D^{20} = +43.8^\circ$
8		racemic
8A		$[\alpha]_D^{20} = -28.9^\circ$
8B		$[\alpha]_D^{20} = +25.7^\circ$
9		racemic

Compound	Structure	Optical rotation
9A		$[\alpha]_{\text{D}}^{20} = -40.6^{\circ}$
9B		$[\alpha]_{\text{D}}^{20} = +42.6^{\circ}$
10		racemic
10A		$[\alpha]_{\text{D}}^{20} = -46.2^{\circ}$
10B		$[\alpha]_{\text{D}}^{20} = +43.0^{\circ}$
11		racemic

Compound	Structure	Optical rotation
11A		$[\alpha]_D^{20} = -31.4^\circ$
11B		$[\alpha]_D^{20} = +29.4^\circ$
12		racemic
12A		$[\alpha]_D^{20} = +50.2^\circ$
12B		$[\alpha]_D^{20} = -51.0^\circ$
13		racemic

Compound	Structure	Optical rotation
13A		[α] _D ²⁰ = +43.2°
13B		[α] _D ²⁰ = -45.9°

ANTIVIRAL ACTIVITY OF THE COMPOUNDS OF THE INVENTION

DENV-2 antiviral assay

- 5 The antiviral activity of all the compounds of the invention was tested the against DENV-2 16681 strain which was labeled with enhanced green fluorescent protein (eGFP). The culture medium consists of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50 mg/mL) and 2 mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in
- 10 culture medium and 25 μ L was added to 384-well plates (2500 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final concentration in 100% DMSO (200 nL). In addition, each compound concentration is tested in quadruplicate (final concentration range: 25 μ M – 0.000064 μ M or
- 15 2.5 μ M – 0.000064 μ M for the most active compounds). Finally, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound), cell controls (containing cells in the absence of virus and compound) and medium controls (containing medium in the absence of cells, virus and compounds). To the wells assigned as medium control, 25 μ L of culture
- 20 medium was added instead of Vero cells. Once the cells were added to the plates, the plates were incubated for 30 minutes at room temperature to allow the cells to distribute evenly within the wells. Next, the plates were incubated in a fully humidified incubator (37°C, 5% CO₂) until the next day. Then, DENV-2 strain 16681, labeled with eGFP, was added at a multiplicity of infection (MOI) of 0.5.
- 25 Therefore, 15 μ L of virus suspension was added to all the wells containing test

compound and to the wells assigned as virus control. In parallel, 15 μ L of culture medium was added to the medium and cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37°C, 5% CO₂). At the day of the read out, the eGFP fluorescence was measured using an automated
 5 fluorescence microscope at 488 nm (blue laser). Using an in-house LIMS system, inhibition dose response curves for each compound were calculated and the half maximal effective concentration (EC₅₀) was determined. Therefore, the percent inhibition (I) for every test concentration is calculated using the following formula: $I = 100 \cdot (S_T - S_{CC}) / (S_{VC} - S_{CC})$; S_T, S_{CC} and S_{VC} are the amount of eGFP signal in the
 10 test compound, cell control and virus control wells, respectively. The EC₅₀ represents the concentration of a compound at which the virus replication is inhibited with 50%, as measured by a 50% reduction of the eGFP fluorescent intensity compared to the virus control. The EC₅₀ is calculated using linear interpolation (Table 1).

15

In parallel, the toxicity of the compounds was assessed on the same plates. Once the read-out for the eGFP signal was done, 40 μ L of ATPlite, a cell viability stain, was added to all wells of the 384-well plates. ATP is present in all metabolically active cells and the concentration declines very rapidly when the cells undergo
 20 necrosis or apoptosis. The ATPLite assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin. The plates were incubated for 10 minutes at room temperature. Next, the plates were measured on a ViewLux. The half maximal cytotoxic concentration (CC₅₀) was also determined, defined as the concentration required to reduce the luminescent
 25 signal by 50% compared to that of the cell control wells. Finally, the selectivity index (SI) was determined for the compounds, which was calculated as followed:
 $SI = CC_{50} / EC_{50}$.

30 Table 1: EC₅₀, CC₅₀, and SI for the compounds of the invention in the DENV-2 antiviral assay

compound#	EC ₅₀ (μ M)	N	CC ₅₀ (μ M)	N	SI	N
1	0.0056	4	13	4	2070	4
1A	0.22	3	13	3	50	3
1B	0.0036	6	12	6	3578	6
2	0.0089	4	12	4	1400	4
2A	0.32	3	18	3	46	3
2B	0.0025	3	13	5	3750	3

compound#	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
3	0.0055	4	9.5	4	1760	4
3A	0.0023	4	9.6	7	4530	4
3B	0.59	3	12	3	19	3
4	0.0067	3	9.7	3	1440	3
4A	0.0036	4	12	6	3878	4
4B	1.1	3	14	3	11	3
5	0.0046	3	9.3	3	2040	3
5A	0.0014	4	9.8	4	7000	4
5B	0.76	3	14	4	19	3
6	0.0062	4	14	4	1940	4
6A	0.28	4	17	4	49	4
6B	0.0025	10	12	10	4900	10
7	0.0023	3	11	3	4670	3
7A	0.79	5	21	5	26	5
7B	0.0010	9	12	10	10000	9
8	0.0044	3	>25	3	>6100	3
8A	0.46	6	>25	6	>81	6
8B	0.0019	7	76	7	>49900	7
9A	1.0	3	13	3	12	3
9B	0.0014	3	11	3	8440	3
10A	1.3	4	11	4	8.4	4
10B	0.0022	3	11	3	5470	3
11	0.0023	3	22	3	8650	3
11A	0.33	3	>25	3	>94	3
11B	0.0016	3	>25	3	>33700	3
12	0.011	3	11	3	966	3
12A	0.0023	3	12	3	5020	3
12B	0.40	3	11	3	27	3
13	0.0049	3	13	3	2630	3
13A	0.0035	3	12	3	3970	3
13B	0.28	3	>25	3	>123	3

N= the number of independent experiments in which the compounds were tested.

Tetravalent reverse transcriptase quantitative-PCR (RT-qPCR) assay

The antiviral activity of the compounds of the invention was tested against DENV-1 strain TC974#666 (NCPV), DENV-2 strain 16681, DENV-3 strain H87 (NCPV) and DENV-4 strain H241 (NCPV) in a RT-qPCR assay. Therefore, Vero cells were infected with either DENV-1, or -2, or -3, or -4 in the presence or absence of test compounds. At day 3 post-infection, the cells were lysed and cell lysates were used to prepare cDNA of both a viral target (the 3'UTR of DENV; Table 2) and a

cellular reference gene (β -actin, Table 2). Subsequently, a duplex real time PCR was performed on a Lightcycler480 instrument. The generated Cp value is inversely proportional to the amount of RNA expression of these targets. Inhibition of DENV replication by a test compound results in a shift of Cp's for the 3'UTR gene. On the other hand, if a test compound is toxic to the cells, a similar effect on β -actin expression will be observed. The comparative $\Delta\Delta$ Cp method is used to calculate EC₅₀, which is based on the relative gene expression of the target gene (3'UTR) normalized with the cellular housekeeping gene (β -actin). In addition, CC₅₀ values are determined based on the Cp values acquired for the housekeeping gene β -actin.

Table 2: Primers and probes used for the real-time, quantitative RT-PCR.

Primer/probe	Target	Sequence ^{a, b}
F3utr258	DENV 3'-UTR	5'-CGGTTAGAGGAGACCCCTC-3'
R3utr425	DENV 3'-UTR	5'-GAGACAGCAGGATCTCTGGTC-3'
P3utr343	DENV 3'-UTR	<i>FAM</i> -5'-AAGGACTAG- <i>ZEN</i> -AGGTTAGAGGAGACCCCCC-3'- <i>IABkFQ</i>
Factin743	β -actin	5'-GGCCAGGTCATCACCATT-3'
Ractin876	β -actin	5'-ATGTCCACGTCACACTTCATG-3'
Pactin773	β -actin	<i>HEX</i> -5'-TTCCGCTGC- <i>ZEN</i> -CCTGAGGCTCTC-3'- <i>IABkFQ</i>

^a Reporter dyes (FAM, HEX) and quenchers (ZEN and IABkFQ) elements are indicated in bold and italics.

^b The nucleotide sequence of the primers and probes were selected from the conserved region in the 3'UTR region of the dengue virus genome, based on the alignment of 300 nucleotide sequences of the four dengue serotypes deposited in Genbank (Gong et al., 2013, Methods Mol Biol, Chapter 16).

The culture medium consisted of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50mg/mL) and 2mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 75 μ L/well was added in 96-well plates (10000 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final

concentration in 100% DMSO (500nL; final concentration range: 25 μ M – 0.000064 μ M or 2.5 μ M – 0.000064 μ M for the most active compounds). In addition, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound) and cell controls (containing cells in the absence of virus and compound). Once the cells were added in the plates, the plates were incubated in a fully humidified incubator (37°C, 5% CO₂) until the next day. Dengue viruses serotype-1, 2, 3 and 4 were diluted in order to obtain a Cp of ~22-24 in the assay. Therefore, 25 μ L of virus suspension was added to all the wells containing test compound and to the wells assigned as virus control. In parallel, 25 μ L of culture medium was added to the cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37°C, 5% CO₂). After 3 days, the supernatant was removed from the wells and the cells were washed twice with ice-cold PBS (~100 μ L). The cell pellets within the 96-well plates were stored at -80°C for at least 1 day. Next, RNA was extracted using the Cells-to-CT™ lysis kit, according to the manufacturer's guideline (Life Technologies). The cell lysates can be stored at -80°C or immediately used in the reverse transcription step.

In preparation of the reverse transcription step, mix A (table 3A) was prepared and 7.57 μ L/well was dispensed in a 96-well plate. After addition of 5 μ L of the cell lysates, a five minute denaturation step at 75°C was performed (table 3B). Afterwards, 7.43 μ L of mix B was added (table 3C) and the reverse transcription step was initiated (table 3D) to generate cDNA.

Finally, a RT-qPCR mix was prepared, mix C (table 4A), and 22.02 μ L/well was dispensed in 96-well LightCycler qPCR plates to which 3 μ L of cDNA was added and the qPCR was performed according to the conditions in table 4B on a LightCycler 480.

Using the LightCycler software and an in-house LIMS system, dose response curves for each compound were calculated and the half maximal effective concentration (EC₅₀) and the half maximal cytotoxic concentration (CC₅₀) were determined (Tables 5-8).

Table 3: cDNA synthesis using Mix A, denaturation, Mix B and reverse transcription.

A Mix A

Plates	8				
Samples	828			Reaction Vol. (μl)	20
Mix Item	Concentration			Volume for (μl)	
	Unit	Stock	Final	1 sample	x samples
Milli-Q H ₂ O				7.27	6019.56
R3utr425	μ M	20	0.27	0.15	124.20
Ractin876	μ M	20	0.27	0.15	124.20
Volume mix/well (μl)				7.57	
Cell lysates				5.00	

B Denaturation step:

Step	Temp	Time
Denaturation	75°C	5'
Hold	4°C	hold

C Mix B

Samples	864				
Mix Item	Concentration			Volume for (μl)	
	Unit	Stock	Final	1 sample	x samples
Expand HIFI buffer 2	X	10.00	1.00	2.00	1728.0
MgCl ₂	mM	25.00	3.50	2.80	2419.2
dNTPs	mM	10.00	1.00	2.00	1728.0
Rnase inhibitor	U/ μ l	40.00	1.00	0.50	432.0
Expand RT	U/ μ l	50.00	0.33	0.13	112.3
Total Volume Mix (μl)				7.43	

D Protocol cDNA synthesis

Step	Temp	Time
Rev transc	42°C	30'
Denaturation	99°C	5'
Hold	4°C	hold

Table 4: qPCR mix and protocol.

A Mix C

Samples	833			Reaction Vol. (μ l)	25
Mix Item	Concentration			Volume for (μ l)	
	Unit	Stock	Final	1 sample	x samples
H ₂ O PCR grade Roche				7.74	6447.42
Roche 2xMM mix	X	2	1	12.50	10412.50
F3utr258	μ M	20	0.3	0.38	316.54
R3utr425	μ M	20	0.3	0.38	316.54
P3utr343	μ M	20	0.1	0.13	108.29
Factin743	μ M	20	0.3	0.38	316.54
Ractin876	μ M	20	0.3	0.38	316.54
Pactin773	μ M	20	0.1	0.13	108.29
Volume Mix / Tube (μl)				22.02	
cDNA				3.00	

B Protocol qPCR3

Step	Temp	Time	Ramp rate	
preincub/denat	95°C	10 min	4.4	
Denaturation	95°C	10 sec	4.4	40 cycles
annealing	58°C	1 min	2.2	
Elongation	72°C	1 sec	4.4	
Cooling	40°C	10 sec	1.5	

Table 5: EC₅₀, CC₅₀, and SI for the compounds against serotype 1 in the RT-qPCR5 assays

compound#	Protocol A					
	RT-qPCR serotype 1 TC974#666					
	EC ₅₀ (μ M)	N	CC ₅₀ (μ M)	N	SI	N
1B	0.0044	5	5.1	4	1110	4
2B	0.0024	3	4.8	2	2670	2
3A	0.0036	3	4.5	3	1210	3
4A	0.0039	3	4.4	3	1270	3
4B	0.70	3	>2.5	4	>4.6	3

Protocol A						
RT-qPCR serotype 1 TC974#666						
compound#	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
5A	0.0026	4	4.7	4	1650	4
6B	0.0031	10	4.8	10	1590	10
7B	0.0051	3	4.1	3	802	3
8B	0.0081	3	>2.5	3	>454	3
9B	0.0027	3	>2.5	3	>1800	3
10B	0.0017	3	>2.5	3	>1810	3
11B	0.0078	3	>2.5	3	>352	3
12A	0.0033	3	>2.5	2	>934	2
13A	0.0063	3	>2.5	2	>416	2

N= the number of independent experiments in which the compounds were tested.

Table 6: EC₅₀, CC₅₀, and SI for the compounds against serotype 2 in the RT-qPCR assays

5

Protocol A						
RT-qPCR serotype 2 16681						
compound#	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.0036	4	3.8	4	1100	4
2B	0.0032	3	5.3	2	1880	2
3A	0.0022	4	9.5	4	4860	4
4A	0.0043	3	3.4	3	894	3
4B	1.0	3	13	3	17	3
5A	0.0030	3	7.6	3	2680	3
6B	0.0020	11	7.9	11	4400	11
7B	0.00096	4	5.0	4	5780	4
8B	0.0023	4	14	4	5510	4
9B	0.0012	3	12	3	11900	3
10B	0.0023	3	10	3	2670	3
11B	0.0020	3	16	3	4840	3
12A	0.0044	3	>2.5	3	>794	3
13A	0.0015	3	>2.5	3	>4280	3

N= the number of independent experiments in which the compounds were tested.

Table 7: EC₅₀, CC₅₀, and SI for the compounds against serotype 3 in the RT-qPCR assays

compound#	Protocol A					
	RT-qPCR serotype 3 H87					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.056	5	2.4	4	46	4
2B	0.029	3	3.6	2	156	2
3A	0.029	3	4.0	3	169	3
4A	0.027	3	3.6	3	179	3
4B	>1.9	3	8.6	4	7.6	1
5A	0.020	3	4.3	3	214	3
6B	0.028	10	4.5	9	253	9
7B	0.030	3	3.7	2	155	2
8B	0.050	3	>2.5	3	>83	3
9B	0.016	3	>2.5	3	>191	3
10B	0.016	3	>2.5	3	>199	3
11B	0.034	3	>2.5	3	>139	3
12A	0.040	3	>2.5	3	>67	3
13A	0.043	3	>2.5	3	>78	3

N= the number of independent experiments in which the compounds were tested.

5

Table 8: EC₅₀, CC₅₀, and SI for the compounds against serotype 4 in the RT-qPCR assays



compound#	Protocol A					
	RT-qPCR serotype 4 H241					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.25	4	2.9	4	12	4
2B	0.17	3	5.9	2	33	2
3A	0.19	4	6.2	3	32	3
4A	0.21	3	2.2	3	11	3
4B	>2.5	3	9.4	4	NA	NA
5A	0.21	3	3.8	3	16	3
6B	0.14	11	4.1	10	27	10
7B	0.12	4	3.1	3	25	3
8B	0.12	4	9.0	4	98	4
9B	0.11	3	2.9	3	23	3
10B	0.16	3	>2.0	3	>13	3

Protocol A						
RT-qPCR serotype 4 H241						
compound#	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
11B	0.28	3	7.6	3	20	3
12A	0.24	3	6.1	3	24	3
13A	0.27	3	2.6	3	>9.4	3

N= the number of independent experiments in which the compounds were tested.
NA= not approved.

5 Prior art examples.

Compounds (56) and (170) disclosed in WO-2013/045516 have been tested in an analogous DENV-2 antiviral assay as the compounds of the present invention and their reported activity is listed below.

	compound (56) of WO-2013/045516
	compound (170) of WO-2013/045516

10


Table 9 : EC₅₀, CC₅₀, and SI for compounds (56) and(170) disclosed in the DENV-2 antiviral assay

compound#	EC ₅₀ (μM)	CC ₅₀ (μM)	SI
(56) of WO-2013/045516	0.45	> 139	> 312
(170) of WO-2013/045516	0.44	26	58

15



Claims

1. A compound having formula (I)














5

a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein the compounds are selected from the group comprising:



10





5

2. A pharmaceutical composition comprising a compound according to claim 1 or its stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers.

10

3. A compound according to claim 1 or its stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 2 for use as a medicament.

4. A compound according to claim 1 or its stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 2 for use in the treatment of dengue.

5

5. A use of a compound as represented by any of the structural formula from claim 1, a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group for inhibiting the replication of dengue virus(es) in a biological sample or patient.


10


6. The use of a compound according to claim 6 further comprising co-administering an additional therapeutic agent.

15

7. The use of claim 6 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.

8. The compound as claimed in claim 1 wherein the compound is selected from





or a pharmaceutically acceptable salt, solvate or polymorph thereof.

9. A pharmaceutical composition comprising a compound according to claim 8,
 5 a pharmaceutically acceptable salt, solvate or polymorph thereof together
 with one or more pharmaceutically acceptable excipients, diluents or carriers.
10. A compound according to claim 8, a pharmaceutically acceptable salt,
 10 solvate or polymorph thereof or a pharmaceutical composition according to
 claim 8 for use as a medicament.
11. A compound according to claim 8, a pharmaceutically acceptable salt,
 15 solvate or polymorph thereof or a pharmaceutical composition according to
 claim 10 for use in the treatment of dengue.
12. A use of a compound as represented by any of the structural formula from
 claim 8, a pharmaceutically acceptable salt, solvate or polymorph thereof
 comprising a mono- or di-substituted indole group for inhibiting the replication
 of dengue virus(es) in a biological sample or patient.

13. The use according to claim 12 which use further comprises co-administering an additional therapeutic agent.
- 5 14. The use according to claim 13 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.